Search Results For:
- Search results for:
- covid 19
(Click + to show provisions)
Agreement title
Effective date
Partner type
Technology
Development stage
European Commision - Curevac, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Pharmaceutical manufacturer
Pharmaceutical manufacturer
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Access to medicines | Donation
- Access to medicines | Pandemic Products
- Access to medicines | Pandemic Products
- Access to medicines | Supply/Purchase of Products
- Business model | Payment Structures
- Consortium structure & management
- Information sharing & data safety | Confidentiality
- Information sharing & data safety | Data management
- Information sharing & data safety | Information sharing
- IP ownership & licensing | Exploitation of results
- IP ownership & licensing | Ownership of results
- Liability | Indemnity / indemnification
- Liability | Insurance
- Liability | Limitation of liability/damage
- Liability | Representations & Warranties
- Other | Conflict of Interest
- Other | Dispute resolution
- Other | Regulatory strategy
- Term & termination | Effect of termination
- Term & termination | Termination & withdrawal
European Commision - Astrazeneca, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Pharmaceutical manufacturer
Vaccine manufacturer
Pharmaceutical manufacturer
Vaccine manufacturer
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Access to medicines | Donation
- Access to medicines | Supply/Purchase of Products
- Business model | Payment Structures
- Consortium structure & management
- Information sharing & data safety | Confidentiality
- Information sharing & data safety | Data management
- IP ownership & licensing | Exploitation of results
- IP ownership & licensing | Ownership of results
- Liability | Indemnity / indemnification
- Liability | Limitation of liability/damage
- Liability | Representations & Warranties
- Other | Dispute resolution
- Other | Regulatory strategy
- Term & termination | Effect of termination
- Term & termination | Term of agreement
UK Government - AstraZeneca, COVID-19 Vaccine Supply Agreement
2020
Government
Multinational pharmaceutical company
Multinational pharmaceutical company
Vaccine
Commercialization
- Access to medicines | Donation
- Access to medicines | Supply/Purchase of Products
- Business model | Payment Structures
- Information sharing & data safety | Confidentiality
- IP ownership & licensing | Ownership of background IP
- IP ownership & licensing | Ownership of results
- Liability | Limitation of liability/damage
- Liability | Representations & Warranties
- Other | Regulatory strategy
- Term & termination | Effect of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
DoD - Moderna, COVID-19, Vaccine Supply Agreement
2020
Government
Multinational pharmaceutical company
Vaccine manufacturer
Multinational pharmaceutical company
Vaccine manufacturer
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Early clinical (through Phase 2)
Late clinical (Phase 3)
Sanofi - Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
2020
Biotechnology company
Multinational pharmaceutical company
Multinational pharmaceutical company
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
- Access to medicines | Donation
- Access to medicines | Pandemic Products
- Business model | Payment Structures
- Information sharing & data safety | Technology transfer
- Information sharing & data safety | Technology transfer
- IP ownership & licensing | Ownership of results
- Open sciences & open data | Publication
- Other | Dispute resolution
- Term & termination | Termination & withdrawal
Fiocruz - AstraZeneca, COVID-19 Technological Order Agreement
2021
Multinational pharmaceutical company
Other nonprofit
Other nonprofit
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Access to medicines | Supply/Purchase of Products
- Business model | Payment Structures
- Consortium structure & management | Roles & Responsibilities
- Information sharing & data safety | Confidentiality
- Information sharing & data safety | Information sharing
- Information sharing & data safety | Technology transfer
- IP ownership & licensing | Use of background IP
- Liability | Limitation of liability/damage
- Liability | Representations & Warranties
- Other | Dispute resolution
- Other | Regulatory strategy
- Term & termination
- Term & termination | Termination & withdrawal
Israel - Pfizer, Epidemiological Evidence Collaboration Agreement
2021
Biotechnology company
Government
Vaccine manufacturer
Government
Vaccine manufacturer
Vaccine
Late clinical (Phase 3)
Commercialization
Field Testing
Commercialization
Field Testing
- Business model | Payment Structures
- Consortium structure & management
- Consortium structure & management
- Information sharing & data safety | Confidentiality
- Information sharing & data safety | Data management
- Information sharing & data safety | Information sharing
- IP ownership & licensing | Ownership of background IP
- IP ownership & licensing | Ownership of results
- Liability | Representations & Warranties
- Open sciences & open data | Publication
BARDA - Moderna, COVID-19 Vaccine Development Agreement
2020
Government
Multinational pharmaceutical company
Vaccine manufacturer
Multinational pharmaceutical company
Vaccine manufacturer
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Early clinical (through Phase 2)
Late clinical (Phase 3)
- Information sharing & data safety | Confidentiality
- Information sharing & data safety | Data management
- IP ownership & licensing | Access to results
- IP ownership & licensing | Ownership of results
- IP ownership & licensing | Protection of results
- Liability | Limitation of liability/damage
- Other | Conflict of Interest
Natick Contracting Division - Ology Bioservices, COVID-19 Procurement Agreement
2020
Government
Pharmaceutical manufacturer
Pharmaceutical manufacturer
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
- Access to medicines | Outbreak preparedness
- Access to medicines | Pandemic Products
- Business model | Payment Structures
- Information sharing & data safety | Confidentiality
- Information sharing & data safety | Information sharing
- IP ownership & licensing | Access to results
- IP ownership & licensing | Exploitation of results
- IP ownership & licensing | Ownership of background IP
- IP ownership & licensing | Ownership of results
- IP ownership & licensing | Protection of results
- IP ownership & licensing | Protection of results
- IP ownership & licensing | Use of background IP
- Liability | Indemnity / indemnification
- Liability | Limitation of liability/damage
- Open sciences & open data | Publication
- Other | Dispute resolution
- Other | Regulatory strategy
- Term & termination | Effect of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
2020
Biotechnology company
Government
Government
Vaccine
Preclinical
Commercialization
Commercialization
CEPI - Novavax, COVID-19 Vaccine Funding Agreement
2020
Biotechnology company
Funder
Vaccine manufacturer
Funder
Vaccine manufacturer
Vaccine
Commercialization
- Access to medicines | Equitable access
- Access to medicines | Pandemic Products
- Access to medicines | Affordable or reasonable pricing
- Access to medicines | Public health licenses
- Access to medicines | Supply/Purchase of Products
- Information sharing & data safety | Information sharing
- IP ownership & licensing | Access to results
- IP ownership & licensing | Ownership of background IP
- IP ownership & licensing | Ownership of results
- IP ownership & licensing | Protection of results
- Liability | Indemnity / indemnification
- Liability | Insurance
- Liability | Limitation of liability/damage
- Liability | Representations & Warranties
- Open sciences & open data | Open data
- Open sciences & open data | Publication
- Other | Regulatory strategy
- Term & termination | Effect of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
2020
Government
Pharmaceutical manufacturer
Vaccine manufacturer
Pharmaceutical manufacturer
Vaccine manufacturer
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Access to medicines | Supply/Purchase of Products
- Information sharing & data safety | Information sharing
- Information sharing & data safety | Information sharing
- IP ownership & licensing | Access to results
- IP ownership & licensing | Ownership of background IP
- IP ownership & licensing | Ownership of results
- IP ownership & licensing | Ownership of results
- IP ownership & licensing | Protection of results
- IP ownership & licensing | Use of background IP
- Liability | Limitation of liability/damage
- Liability | Representations & Warranties
- Open sciences & open data | Publication
- Other | Regulatory strategy
- Term & termination | Effect of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Pfizer/BioNTech-Dominican Republic Binding Term Sheet
2021
Biotechnology company
Government
Multinational pharmaceutical company
Government
Multinational pharmaceutical company
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Access to medicines | Supply/Purchase of Products
- Information sharing & data safety | Confidentiality
- Information sharing & data safety | Exceptions and limitations to the confidentiality obligations
- Information sharing & data safety | Information sharing
- IP ownership & licensing | Ownership of background IP
- Liability | Indemnity / indemnification
- Liability | Representations & Warranties
- Liability | Representations & Warranties
- Other | Dispute resolution
- Other | Regulatory strategy
- Term & termination | Term of agreement
Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
2021
Biotechnology company
Government
Multinational pharmaceutical company
Government
Multinational pharmaceutical company
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Access to medicines | Supply/Purchase of Products
- Information sharing & data safety | Confidentiality
- Information sharing & data safety | Information sharing
- IP ownership & licensing | Ownership of background IP
- Liability | Indemnity / indemnification
- Other | Dispute resolution
- Other | Regulatory strategy
Regeneron - ATI, COVID-19 Antibodies Manufacturing Agreement
2020
Government
Pharmaceutical manufacturer
Pharmaceutical manufacturer
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
- Access to medicines | Supply/Purchase of Products
- Information sharing & data safety | Information sharing
- IP ownership & licensing | Access to results
- IP ownership & licensing | Ownership of background IP
- IP ownership & licensing | Ownership of results
- IP ownership & licensing | Ownership of results
- IP ownership & licensing | Use of background IP
- Liability | Limitation of liability/damage
- Other | Regulatory strategy
US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
2020
Government
Multinational pharmaceutical company
Pharmaceutical manufacturer
Multinational pharmaceutical company
Pharmaceutical manufacturer
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Late clinical (Phase 3)
Commercialization
Field Testing
- Access to medicines | Supply/Purchase of Products
- Business model | Payment Structures
- Business model | Payment Structures
- Information sharing & data safety | Confidentiality
- Information sharing & data safety | Information sharing
- IP ownership & licensing | Access to results
- Liability | Limitation of liability/damage
- Open sciences & open data | Publication
- Other | Dispute resolution
- Other | Regulatory strategy
UK Government - Roche, REGN-COV2 Supply Agreement for Pandemic Purposes
2021
Government
Multinational pharmaceutical company
Multinational pharmaceutical company
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
GHIAA2019\MapguideSearch Object
(
[search_parameters] => Array
(
[qs] => covid 19
)
[filters] => Array
(
[text_search] => covid 19
)
[child_filters] => Array
(
)
[agreement_args] =>
[provision_args] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[post__in] => Array
(
[0] => 3436
[1] => 3435
[2] => 3434
[3] => 3433
[4] => 3431
[5] => 3430
[6] => 3428
[7] => 3427
[8] => 3426
[9] => 3424
[10] => 3422
[11] => 3421
[12] => 3420
[13] => 3372
[14] => 3371
[15] => 3370
[16] => 3368
[17] => 3366
[18] => 3364
[19] => 3363
[20] => 3361
[21] => 3360
[22] => 3356
[23] => 3354
[24] => 3352
[25] => 3221
[26] => 3220
[27] => 3219
[28] => 3218
[29] => 3217
[30] => 3216
[31] => 3215
[32] => 2956
[33] => 2961
[34] => 2965
[35] => 2947
[36] => 2960
[37] => 2964
[38] => 2958
[39] => 2949
[40] => 2957
[41] => 2962
[42] => 2945
[43] => 2909
[44] => 2908
[45] => 2907
[46] => 2893
[47] => 2892
[48] => 2890
[49] => 2889
[50] => 2888
[51] => 2886
[52] => 2885
[53] => 2824
[54] => 2823
[55] => 2822
[56] => 2821
[57] => 2820
[58] => 2819
[59] => 2744
[60] => 2749
[61] => 2748
[62] => 2740
[63] => 2743
[64] => 2742
[65] => 2741
[66] => 2739
[67] => 2738
[68] => 2737
[69] => 2736
[70] => 2735
[71] => 2734
[72] => 2543
[73] => 2540
[74] => 2541
[75] => 2542
[76] => 2544
[77] => 2545
[78] => 2546
[79] => 2547
[80] => 2548
[81] => 2549
[82] => 2553
[83] => 2554
[84] => 2457
[85] => 2459
[86] => 2460
[87] => 2461
[88] => 2462
[89] => 2463
[90] => 2464
[91] => 2465
[92] => 2466
[93] => 2467
[94] => 2470
[95] => 2472
[96] => 2473
[97] => 2474
[98] => 2475
[99] => 2476
[100] => 2477
[101] => 2478
[102] => 2479
[103] => 2480
[104] => 2481
[105] => 2482
[106] => 2483
[107] => 2471
[108] => 2454
[109] => 2452
[110] => 2450
[111] => 2449
[112] => 2448
[113] => 2445
[114] => 2444
[115] => 2443
[116] => 2442
[117] => 2441
[118] => 2440
[119] => 2425
[120] => 2426
[121] => 2424
[122] => 2422
[123] => 3436
[124] => 3435
[125] => 3434
[126] => 3433
[127] => 3431
[128] => 3430
[129] => 3428
[130] => 3427
[131] => 3426
[132] => 3424
[133] => 3422
[134] => 3421
[135] => 3420
[136] => 3372
[137] => 3371
[138] => 3370
[139] => 3368
[140] => 3366
[141] => 3364
[142] => 3363
[143] => 3361
[144] => 3360
[145] => 3356
[146] => 3354
[147] => 3352
[148] => 3221
[149] => 3220
[150] => 3219
[151] => 3218
[152] => 3217
[153] => 3216
[154] => 3215
[155] => 2909
[156] => 2908
[157] => 2907
[158] => 2893
[159] => 2892
[160] => 2890
[161] => 2889
[162] => 2888
[163] => 2886
[164] => 2885
[165] => 2744
[166] => 2749
[167] => 2748
[168] => 2740
[169] => 2743
[170] => 2742
[171] => 2741
[172] => 2739
[173] => 2738
[174] => 2737
[175] => 2736
[176] => 2735
[177] => 2734
[178] => 2543
[179] => 2540
[180] => 2541
[181] => 2542
[182] => 2544
[183] => 2545
[184] => 2546
[185] => 2547
[186] => 2548
[187] => 2549
[188] => 2553
[189] => 2554
[190] => 2457
[191] => 2459
[192] => 2460
[193] => 2461
[194] => 2462
[195] => 2463
[196] => 2464
[197] => 2465
[198] => 2466
[199] => 2467
[200] => 2470
[201] => 2472
[202] => 2473
[203] => 2474
[204] => 2475
[205] => 2476
[206] => 2477
[207] => 2478
[208] => 2479
[209] => 2480
[210] => 2481
[211] => 2482
[212] => 2483
[213] => 2471
[214] => 3406
[215] => 3304
[216] => 3127
[217] => 3126
[218] => 3125
[219] => 3124
[220] => 3123
[221] => 3122
[222] => 3121
[223] => 3120
[224] => 3119
[225] => 2947
[226] => 2873
[227] => 2872
[228] => 2870
[229] => 2869
[230] => 2868
[231] => 2867
[232] => 2865
[233] => 2824
[234] => 2823
[235] => 2822
[236] => 2454
[237] => 2452
[238] => 2450
[239] => 2449
[240] => 2448
[241] => 2445
[242] => 2444
[243] => 2443
[244] => 2442
[245] => 2441
[246] => 2440
[247] => 2425
[248] => 2426
[249] => 2424
[250] => 2422
)
)
[text_agreement_args] => Array
(
[post_type] => agreement
[posts_per_page] => -1
[s] => covid 19
)
[text_provision_args] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[s] => covid 19
)
[agreement_ids] => Array
(
)
[agreement_q_rslts] =>
[provision_q_rslts] =>
[text_agreement_q_rslts] => WP_Query Object
(
[query] => Array
(
[post_type] => agreement
[posts_per_page] => -1
[s] => covid 19
)
[query_vars] => Array
(
[post_type] => agreement
[posts_per_page] => -1
[s] => covid 19
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[orderby] => title
[order] => ASC
[suppress_filters] =>
[ignore_sticky_posts] =>
[cache_results] => 1
[update_post_term_cache] => 1
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] => 1
[comments_per_page] => 50
[no_found_rows] =>
[search_terms_count] => 2
[search_terms] => Array
(
[0] => covid
[1] => 19
)
[search_orderby_title] => Array
(
[0] => wpry_posts.post_title LIKE '{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}covid{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}'
[1] => wpry_posts.post_title LIKE '{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}19{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}'
)
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wpry_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT DISTINCT wpry_posts.* FROM wpry_posts INNER JOIN wpry_postmeta AS a ON (a.post_id = wpry_posts.ID) LEFT JOIN wpry_postmeta AS b ON (((b.meta_id = a.meta_id + @@auto_increment_increment)) AND ((b.meta_key LIKE CONCAT('\_', a.meta_key)))) LEFT JOIN wpry_posts AS c ON ((c.post_name = b.meta_value) AND (c.post_type = 'acf-field') AND ((c.post_content LIKE '%:"text"%') OR (c.post_content LIKE '%:"textarea"%') OR (c.post_content LIKE '%:"wysiwyg"%') OR (c.post_content LIKE '%:"checkbox"%'))) WHERE 1=1 AND (((b.meta_id IS NOT NULL) AND (c.ID IS NOT NULL) AND (a.meta_value LIKE '%covid%') AND (a.meta_value LIKE '%19%')) OR (((wpry_posts.post_title LIKE '%covid%') OR (wpry_posts.post_content LIKE '%covid%') OR (wpry_posts.post_excerpt LIKE '%covid%')) AND ((wpry_posts.post_title LIKE '%19%') OR (wpry_posts.post_content LIKE '%19%') OR (wpry_posts.post_excerpt LIKE '%19%')))) AND wpry_posts.post_type = 'agreement' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled') ORDER BY wpry_posts.post_title ASC
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 2438
[post_author] => 5
[post_date] => 2021-01-19 06:43:39
[post_date_gmt] => 2021-01-19 06:43:39
[post_content] =>
[post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-agreement-contract-no-75a50122c00034-for-development-of-an-mrna-vaccine-for-sars-cov-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-20 13:40:15
[post_modified_gmt] => 2021-07-20 13:40:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2438
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 2882
[post_author] => 6
[post_date] => 2021-05-14 14:03:29
[post_date_gmt] => 2021-05-14 14:03:29
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-20 13:54:05
[post_modified_gmt] => 2021-07-20 13:54:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2882
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 2446
[post_author] => 5
[post_date] => 2021-01-19 09:42:42
[post_date_gmt] => 2021-01-19 09:42:42
[post_content] =>
[post_title] => DoD - Moderna, COVID-19, Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => award-contract-no-w911qy20c0100-by-and-between-modernatx-inc-and-the-department-of-defense
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-20 13:27:18
[post_modified_gmt] => 2021-07-20 13:27:18
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2446
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 2538
[post_author] => 5
[post_date] => 2021-03-12 13:41:11
[post_date_gmt] => 2021-03-12 13:41:11
[post_content] =>
[post_title] => European Commision - Astrazeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => advance-purchase-agreement-for-the-production-purchase-and-supply-of-a-covid-19-vaccine-in-the-european-union-with-astrazeneca
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-20 13:25:09
[post_modified_gmt] => 2021-07-20 13:25:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2538
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 2468
[post_author] => 5
[post_date] => 2021-02-25 15:15:43
[post_date_gmt] => 2021-02-25 15:15:43
[post_content] =>
[post_title] => European Commision - Curevac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => advance-purchase-agreement-for-the-development-production-advance-purchase-and-supply-of-a-covid-19-vaccine-for-eu-member-states-with-curevac
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-20 13:23:58
[post_modified_gmt] => 2021-07-20 13:23:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2468
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[5] => WP_Post Object
(
[ID] => 3419
[post_author] => 6
[post_date] => 2021-07-01 01:45:34
[post_date_gmt] => 2021-07-01 01:45:34
[post_content] =>
[post_title] => Fiocruz - AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-01 01:47:20
[post_modified_gmt] => 2021-07-01 01:47:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=3419
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[6] => WP_Post Object
(
[ID] => 3348
[post_author] => 5
[post_date] => 2021-06-30 13:13:40
[post_date_gmt] => 2021-06-30 13:13:40
[post_content] =>
[post_title] => Natick Contracting Division - Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 13:13:40
[post_modified_gmt] => 2021-06-30 13:13:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=3348
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[7] => WP_Post Object
(
[ID] => 3213
[post_author] => 6
[post_date] => 2021-06-28 12:04:36
[post_date_gmt] => 2021-06-28 12:04:36
[post_content] =>
[post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-28 12:04:36
[post_modified_gmt] => 2021-06-28 12:04:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=3213
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[8] => WP_Post Object
(
[ID] => 2817
[post_author] => 5
[post_date] => 2021-04-16 11:58:45
[post_date_gmt] => 2021-04-16 11:58:45
[post_content] =>
[post_title] => Regeneron - ATI, COVID-19 Antibodies Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-20 13:55:11
[post_modified_gmt] => 2021-07-20 13:55:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2817
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[9] => WP_Post Object
(
[ID] => 2420
[post_author] => 5
[post_date] => 2020-12-14 14:59:07
[post_date_gmt] => 2020-12-14 14:59:07
[post_content] =>
[post_title] => Sanofi - Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => collaboration-and-license-agreement-between-sanofi-pasteur-inc-sanofi-and-translate-bio-ma-inc-translate-bio-or-tb-and-first-amendment-co
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-20 13:29:49
[post_modified_gmt] => 2021-07-20 13:29:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2420
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[10] => WP_Post Object
(
[ID] => 2943
[post_author] => 6
[post_date] => 2021-05-28 13:48:32
[post_date_gmt] => 2021-05-28 13:48:32
[post_content] =>
[post_title] => UK Government - AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-20 13:26:21
[post_modified_gmt] => 2021-07-20 13:26:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2943
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[11] => WP_Post Object
(
[ID] => 2732
[post_author] => 5
[post_date] => 2021-03-23 15:54:07
[post_date_gmt] => 2021-03-23 15:54:07
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-statement-of-work-for-rapid-wf10-advanced-research-development-to-large-scale-manufacturing-of-nvx-cov-2373-as-a-vaccine-for-sars-cov-2-coronavirus-under-the-base-agreemen
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-20 13:54:35
[post_modified_gmt] => 2021-07-20 13:54:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2732
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[12] => WP_Post Object
(
[ID] => 2455
[post_author] => 5
[post_date] => 2021-02-25 15:19:51
[post_date_gmt] => 2021-02-25 15:19:51
[post_content] =>
[post_title] => US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-20 13:55:49
[post_modified_gmt] => 2021-07-20 13:55:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2455
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 13
[current_post] => -1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 2438
[post_author] => 5
[post_date] => 2021-01-19 06:43:39
[post_date_gmt] => 2021-01-19 06:43:39
[post_content] =>
[post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-agreement-contract-no-75a50122c00034-for-development-of-an-mrna-vaccine-for-sars-cov-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-20 13:40:15
[post_modified_gmt] => 2021-07-20 13:40:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2438
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 13
[max_num_pages] => 0
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] => 1
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] => 1
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] =>
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] => 1
[query_vars_hash:WP_Query:private] => 1fc2d19f378284cf7496bf5ba612c2e6
[query_vars_changed:WP_Query:private] => 1
[thumbnails_cached] =>
[stopwords:WP_Query:private] => Array
(
[0] => about
[1] => an
[2] => are
[3] => as
[4] => at
[5] => be
[6] => by
[7] => com
[8] => for
[9] => from
[10] => how
[11] => in
[12] => is
[13] => it
[14] => of
[15] => on
[16] => or
[17] => that
[18] => the
[19] => this
[20] => to
[21] => was
[22] => what
[23] => when
[24] => where
[25] => who
[26] => will
[27] => with
[28] => www
)
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)
[text_provision_q_rslts] => WP_Query Object
(
[query] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[s] => covid 19
)
[query_vars] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[s] => covid 19
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[suppress_filters] =>
[ignore_sticky_posts] =>
[cache_results] => 1
[update_post_term_cache] => 1
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] => 1
[comments_per_page] => 50
[no_found_rows] =>
[search_terms_count] => 2
[search_terms] => Array
(
[0] => covid
[1] => 19
)
[search_orderby_title] => Array
(
[0] => wpry_posts.post_title LIKE '{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}covid{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}'
[1] => wpry_posts.post_title LIKE '{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}19{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}'
)
[order] => DESC
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wpry_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT DISTINCT wpry_posts.* FROM wpry_posts INNER JOIN wpry_postmeta AS a ON (a.post_id = wpry_posts.ID) LEFT JOIN wpry_postmeta AS b ON (((b.meta_id = a.meta_id + @@auto_increment_increment)) AND ((b.meta_key LIKE CONCAT('\_', a.meta_key)))) LEFT JOIN wpry_posts AS c ON ((c.post_name = b.meta_value) AND (c.post_type = 'acf-field') AND ((c.post_content LIKE '%:"text"%') OR (c.post_content LIKE '%:"textarea"%') OR (c.post_content LIKE '%:"wysiwyg"%') OR (c.post_content LIKE '%:"checkbox"%'))) WHERE 1=1 AND (((b.meta_id IS NOT NULL) AND (c.ID IS NOT NULL) AND (a.meta_value LIKE '%covid%') AND (a.meta_value LIKE '%19%')) OR (((wpry_posts.post_title LIKE '%covid%') OR (wpry_posts.post_content LIKE '%covid%') OR (wpry_posts.post_excerpt LIKE '%covid%')) AND ((wpry_posts.post_title LIKE '%19%') OR (wpry_posts.post_content LIKE '%19%') OR (wpry_posts.post_excerpt LIKE '%19%')))) AND wpry_posts.post_type = 'provision_document' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled') ORDER BY (CASE WHEN wpry_posts.post_title LIKE '{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}covid 19{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}' THEN 1 WHEN wpry_posts.post_title LIKE '{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}covid{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}' AND wpry_posts.post_title LIKE '{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}19{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}' THEN 2 WHEN wpry_posts.post_title LIKE '{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}covid{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}' OR wpry_posts.post_title LIKE '{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}19{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}' THEN 3 WHEN wpry_posts.post_excerpt LIKE '{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}covid 19{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}' THEN 4 WHEN wpry_posts.post_content LIKE '{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}covid 19{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}' THEN 5 ELSE 6 END), wpry_posts.post_date DESC
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 3436
[post_author] => 6
[post_date] => 2021-07-01 03:48:49
[post_date_gmt] => 2021-07-01 03:48:49
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-22 11:01:08
[post_modified_gmt] => 2021-07-22 11:01:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3436
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 3435
[post_author] => 6
[post_date] => 2021-07-01 03:45:58
[post_date_gmt] => 2021-07-01 03:45:58
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-01 03:45:58
[post_modified_gmt] => 2021-07-01 03:45:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3435
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 3434
[post_author] => 6
[post_date] => 2021-07-01 03:44:18
[post_date_gmt] => 2021-07-01 03:44:18
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-01 03:44:18
[post_modified_gmt] => 2021-07-01 03:44:18
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3434
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 3433
[post_author] => 6
[post_date] => 2021-07-01 03:41:21
[post_date_gmt] => 2021-07-01 03:41:21
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-01 03:41:21
[post_modified_gmt] => 2021-07-01 03:41:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3433
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 3431
[post_author] => 6
[post_date] => 2021-07-01 03:38:49
[post_date_gmt] => 2021-07-01 03:38:49
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-01 03:38:49
[post_modified_gmt] => 2021-07-01 03:38:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3431
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[5] => WP_Post Object
(
[ID] => 3430
[post_author] => 6
[post_date] => 2021-07-01 03:27:51
[post_date_gmt] => 2021-07-01 03:27:51
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-22 13:58:20
[post_modified_gmt] => 2021-07-22 13:58:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3430
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[6] => WP_Post Object
(
[ID] => 3428
[post_author] => 6
[post_date] => 2021-07-01 03:24:00
[post_date_gmt] => 2021-07-01 03:24:00
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-01 03:24:00
[post_modified_gmt] => 2021-07-01 03:24:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3428
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[7] => WP_Post Object
(
[ID] => 3427
[post_author] => 6
[post_date] => 2021-07-01 03:22:23
[post_date_gmt] => 2021-07-01 03:22:23
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-01 03:22:23
[post_modified_gmt] => 2021-07-01 03:22:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3427
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[8] => WP_Post Object
(
[ID] => 3426
[post_author] => 6
[post_date] => 2021-07-01 03:06:23
[post_date_gmt] => 2021-07-01 03:06:23
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-01 03:06:23
[post_modified_gmt] => 2021-07-01 03:06:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3426
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[9] => WP_Post Object
(
[ID] => 3424
[post_author] => 6
[post_date] => 2021-07-01 03:03:57
[post_date_gmt] => 2021-07-01 03:03:57
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-01 03:03:57
[post_modified_gmt] => 2021-07-01 03:03:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3424
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[10] => WP_Post Object
(
[ID] => 3422
[post_author] => 6
[post_date] => 2021-07-01 02:58:21
[post_date_gmt] => 2021-07-01 02:58:21
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-22 15:32:57
[post_modified_gmt] => 2021-07-22 15:32:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3422
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[11] => WP_Post Object
(
[ID] => 3421
[post_author] => 6
[post_date] => 2021-07-01 02:56:30
[post_date_gmt] => 2021-07-01 02:56:30
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-01 02:56:30
[post_modified_gmt] => 2021-07-01 02:56:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3421
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[12] => WP_Post Object
(
[ID] => 3420
[post_author] => 6
[post_date] => 2021-07-01 02:52:05
[post_date_gmt] => 2021-07-01 02:52:05
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-01 02:52:05
[post_modified_gmt] => 2021-07-01 02:52:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3420
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[13] => WP_Post Object
(
[ID] => 3372
[post_author] => 5
[post_date] => 2021-06-30 15:06:19
[post_date_gmt] => 2021-06-30 15:06:19
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 15:06:19
[post_modified_gmt] => 2021-06-30 15:06:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3372
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[14] => WP_Post Object
(
[ID] => 3371
[post_author] => 5
[post_date] => 2021-06-30 15:03:10
[post_date_gmt] => 2021-06-30 15:03:10
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 15:03:10
[post_modified_gmt] => 2021-06-30 15:03:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3371
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[15] => WP_Post Object
(
[ID] => 3370
[post_author] => 5
[post_date] => 2021-06-30 15:01:06
[post_date_gmt] => 2021-06-30 15:01:06
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 15:01:06
[post_modified_gmt] => 2021-06-30 15:01:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3370
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[16] => WP_Post Object
(
[ID] => 3368
[post_author] => 5
[post_date] => 2021-06-30 14:58:39
[post_date_gmt] => 2021-06-30 14:58:39
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 14:58:39
[post_modified_gmt] => 2021-06-30 14:58:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3368
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[17] => WP_Post Object
(
[ID] => 3366
[post_author] => 5
[post_date] => 2021-06-30 14:53:53
[post_date_gmt] => 2021-06-30 14:53:53
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 14:53:53
[post_modified_gmt] => 2021-06-30 14:53:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3366
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[18] => WP_Post Object
(
[ID] => 3364
[post_author] => 5
[post_date] => 2021-06-30 14:47:34
[post_date_gmt] => 2021-06-30 14:47:34
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 14:47:34
[post_modified_gmt] => 2021-06-30 14:47:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3364
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[19] => WP_Post Object
(
[ID] => 3363
[post_author] => 5
[post_date] => 2021-06-30 14:45:00
[post_date_gmt] => 2021-06-30 14:45:00
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 14:45:00
[post_modified_gmt] => 2021-06-30 14:45:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3363
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[20] => WP_Post Object
(
[ID] => 3361
[post_author] => 5
[post_date] => 2021-06-30 14:30:51
[post_date_gmt] => 2021-06-30 14:30:51
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 14:30:51
[post_modified_gmt] => 2021-06-30 14:30:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3361
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[21] => WP_Post Object
(
[ID] => 3360
[post_author] => 5
[post_date] => 2021-06-30 14:28:40
[post_date_gmt] => 2021-06-30 14:28:40
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 14:28:40
[post_modified_gmt] => 2021-06-30 14:28:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3360
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[22] => WP_Post Object
(
[ID] => 3356
[post_author] => 5
[post_date] => 2021-06-30 13:53:23
[post_date_gmt] => 2021-06-30 13:53:23
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 13:53:23
[post_modified_gmt] => 2021-06-30 13:53:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3356
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[23] => WP_Post Object
(
[ID] => 3354
[post_author] => 5
[post_date] => 2021-06-30 13:29:21
[post_date_gmt] => 2021-06-30 13:29:21
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 13:29:21
[post_modified_gmt] => 2021-06-30 13:29:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3354
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[24] => WP_Post Object
(
[ID] => 3352
[post_author] => 5
[post_date] => 2021-06-30 13:24:49
[post_date_gmt] => 2021-06-30 13:24:49
[post_content] =>
[post_title] => Natick Contracting Division - Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 13:24:49
[post_modified_gmt] => 2021-06-30 13:24:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3352
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[25] => WP_Post Object
(
[ID] => 3221
[post_author] => 6
[post_date] => 2021-06-28 12:23:49
[post_date_gmt] => 2021-06-28 12:23:49
[post_content] =>
[post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-28 12:23:49
[post_modified_gmt] => 2021-06-28 12:23:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3221
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[26] => WP_Post Object
(
[ID] => 3220
[post_author] => 6
[post_date] => 2021-06-28 12:22:09
[post_date_gmt] => 2021-06-28 12:22:09
[post_content] =>
[post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-28 12:22:09
[post_modified_gmt] => 2021-06-28 12:22:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3220
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[27] => WP_Post Object
(
[ID] => 3219
[post_author] => 6
[post_date] => 2021-06-28 12:19:29
[post_date_gmt] => 2021-06-28 12:19:29
[post_content] =>
[post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-28 12:19:29
[post_modified_gmt] => 2021-06-28 12:19:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3219
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[28] => WP_Post Object
(
[ID] => 3218
[post_author] => 6
[post_date] => 2021-06-28 12:16:20
[post_date_gmt] => 2021-06-28 12:16:20
[post_content] =>
[post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-28 12:16:20
[post_modified_gmt] => 2021-06-28 12:16:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3218
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[29] => WP_Post Object
(
[ID] => 3217
[post_author] => 6
[post_date] => 2021-06-28 12:14:37
[post_date_gmt] => 2021-06-28 12:14:37
[post_content] =>
[post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-28 12:14:37
[post_modified_gmt] => 2021-06-28 12:14:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3217
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[30] => WP_Post Object
(
[ID] => 3216
[post_author] => 6
[post_date] => 2021-06-28 12:11:22
[post_date_gmt] => 2021-06-28 12:11:22
[post_content] =>
[post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-28 12:11:22
[post_modified_gmt] => 2021-06-28 12:11:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3216
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[31] => WP_Post Object
(
[ID] => 3215
[post_author] => 6
[post_date] => 2021-06-28 12:07:55
[post_date_gmt] => 2021-06-28 12:07:55
[post_content] =>
[post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-28 12:07:55
[post_modified_gmt] => 2021-06-28 12:07:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3215
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[32] => WP_Post Object
(
[ID] => 2909
[post_author] => 6
[post_date] => 2021-05-19 15:13:58
[post_date_gmt] => 2021-05-19 15:13:58
[post_content] =>
[post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-16 15:39:30
[post_modified_gmt] => 2021-06-16 15:39:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2909
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[33] => WP_Post Object
(
[ID] => 2908
[post_author] => 6
[post_date] => 2021-05-19 15:08:05
[post_date_gmt] => 2021-05-19 15:08:05
[post_content] =>
[post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-21 12:18:00
[post_modified_gmt] => 2021-07-21 12:18:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2908
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[34] => WP_Post Object
(
[ID] => 2907
[post_author] => 6
[post_date] => 2021-05-19 14:46:20
[post_date_gmt] => 2021-05-19 14:46:20
[post_content] =>
[post_title] => Novavax – CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-22 14:10:32
[post_modified_gmt] => 2021-07-22 14:10:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2907
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[35] => WP_Post Object
(
[ID] => 2893
[post_author] => 6
[post_date] => 2021-05-19 14:40:45
[post_date_gmt] => 2021-05-19 14:40:45
[post_content] =>
[post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-21 08:56:01
[post_modified_gmt] => 2021-06-21 08:56:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2893
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[36] => WP_Post Object
(
[ID] => 2892
[post_author] => 6
[post_date] => 2021-05-14 19:30:23
[post_date_gmt] => 2021-05-14 19:30:23
[post_content] =>
[post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-02 15:13:39
[post_modified_gmt] => 2021-06-02 15:13:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2892
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[37] => WP_Post Object
(
[ID] => 2890
[post_author] => 6
[post_date] => 2021-05-14 19:14:07
[post_date_gmt] => 2021-05-14 19:14:07
[post_content] =>
[post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-08 12:49:25
[post_modified_gmt] => 2021-06-08 12:49:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2890
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[38] => WP_Post Object
(
[ID] => 2889
[post_author] => 6
[post_date] => 2021-05-14 19:09:07
[post_date_gmt] => 2021-05-14 19:09:07
[post_content] =>
[post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-14 19:09:07
[post_modified_gmt] => 2021-05-14 19:09:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2889
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[39] => WP_Post Object
(
[ID] => 2888
[post_author] => 6
[post_date] => 2021-05-14 19:01:08
[post_date_gmt] => 2021-05-14 19:01:08
[post_content] =>
[post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-20 12:23:46
[post_modified_gmt] => 2021-05-20 12:23:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2888
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[40] => WP_Post Object
(
[ID] => 2886
[post_author] => 6
[post_date] => 2021-05-14 18:21:24
[post_date_gmt] => 2021-05-14 18:21:24
[post_content] =>
[post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-14 18:21:24
[post_modified_gmt] => 2021-05-14 18:21:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2886
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[41] => WP_Post Object
(
[ID] => 2885
[post_author] => 5
[post_date] => 2021-05-14 18:17:37
[post_date_gmt] => 2021-05-14 18:17:37
[post_content] =>
[post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-14 18:17:37
[post_modified_gmt] => 2021-05-14 18:17:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2885
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[42] => WP_Post Object
(
[ID] => 2744
[post_author] => 5
[post_date] => 2021-03-30 15:12:35
[post_date_gmt] => 2021-03-30 15:12:35
[post_content] =>
[post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:21:21
[post_modified_gmt] => 2021-05-17 13:21:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2744
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[43] => WP_Post Object
(
[ID] => 2749
[post_author] => 5
[post_date] => 2021-03-30 15:10:16
[post_date_gmt] => 2021-03-30 15:10:16
[post_content] =>
[post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-01 09:43:25
[post_modified_gmt] => 2021-06-01 09:43:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2749
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[44] => WP_Post Object
(
[ID] => 2748
[post_author] => 5
[post_date] => 2021-03-30 15:05:46
[post_date_gmt] => 2021-03-30 15:05:46
[post_content] =>
[post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => 2748
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:21:40
[post_modified_gmt] => 2021-05-17 13:21:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2748
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[45] => WP_Post Object
(
[ID] => 2740
[post_author] => 5
[post_date] => 2021-03-30 14:54:54
[post_date_gmt] => 2021-03-30 14:54:54
[post_content] =>
[post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:21:50
[post_modified_gmt] => 2021-05-17 13:21:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2740
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[46] => WP_Post Object
(
[ID] => 2743
[post_author] => 5
[post_date] => 2021-03-24 15:11:40
[post_date_gmt] => 2021-03-24 15:11:40
[post_content] =>
[post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:22:13
[post_modified_gmt] => 2021-05-17 13:22:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2743
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[47] => WP_Post Object
(
[ID] => 2742
[post_author] => 5
[post_date] => 2021-03-24 13:37:07
[post_date_gmt] => 2021-03-24 13:37:07
[post_content] =>
[post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-22 14:14:47
[post_modified_gmt] => 2021-07-22 14:14:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2742
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[48] => WP_Post Object
(
[ID] => 2741
[post_author] => 5
[post_date] => 2021-03-24 13:32:55
[post_date_gmt] => 2021-03-24 13:32:55
[post_content] =>
[post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:22:24
[post_modified_gmt] => 2021-05-17 13:22:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2741
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[49] => WP_Post Object
(
[ID] => 2739
[post_author] => 5
[post_date] => 2021-03-24 13:12:14
[post_date_gmt] => 2021-03-24 13:12:14
[post_content] =>
[post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:22:33
[post_modified_gmt] => 2021-05-17 13:22:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2739
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[50] => WP_Post Object
(
[ID] => 2738
[post_author] => 5
[post_date] => 2021-03-24 13:04:24
[post_date_gmt] => 2021-03-24 13:04:24
[post_content] =>
[post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-09 09:03:59
[post_modified_gmt] => 2021-06-09 09:03:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2738
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[51] => WP_Post Object
(
[ID] => 2737
[post_author] => 5
[post_date] => 2021-03-24 13:00:46
[post_date_gmt] => 2021-03-24 13:00:46
[post_content] =>
[post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:23:04
[post_modified_gmt] => 2021-05-17 13:23:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2737
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[52] => WP_Post Object
(
[ID] => 2736
[post_author] => 5
[post_date] => 2021-03-23 18:15:15
[post_date_gmt] => 2021-03-23 18:15:15
[post_content] =>
[post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:23:17
[post_modified_gmt] => 2021-05-17 13:23:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2736
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[53] => WP_Post Object
(
[ID] => 2735
[post_author] => 5
[post_date] => 2021-03-23 18:05:28
[post_date_gmt] => 2021-03-23 18:05:28
[post_content] =>
[post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:23:28
[post_modified_gmt] => 2021-05-17 13:23:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2735
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[54] => WP_Post Object
(
[ID] => 2734
[post_author] => 5
[post_date] => 2021-03-23 18:01:22
[post_date_gmt] => 2021-03-23 18:01:22
[post_content] =>
[post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-07 17:12:58
[post_modified_gmt] => 2021-06-07 17:12:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2734
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[55] => WP_Post Object
(
[ID] => 2543
[post_author] => 5
[post_date] => 2021-03-12 18:15:58
[post_date_gmt] => 2021-03-12 18:15:58
[post_content] =>
[post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:24:40
[post_modified_gmt] => 2021-05-17 13:24:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2543
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[56] => WP_Post Object
(
[ID] => 2540
[post_author] => 5
[post_date] => 2021-03-12 18:12:48
[post_date_gmt] => 2021-03-12 18:12:48
[post_content] =>
[post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-07 13:52:44
[post_modified_gmt] => 2021-07-07 13:52:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2540
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[57] => WP_Post Object
(
[ID] => 2541
[post_author] => 5
[post_date] => 2021-03-12 18:11:14
[post_date_gmt] => 2021-03-12 18:11:14
[post_content] =>
[post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-28 16:06:34
[post_modified_gmt] => 2021-05-28 16:06:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2541
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[58] => WP_Post Object
(
[ID] => 2542
[post_author] => 5
[post_date] => 2021-03-12 14:21:07
[post_date_gmt] => 2021-03-12 14:21:07
[post_content] =>
[post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-28 15:59:01
[post_modified_gmt] => 2021-05-28 15:59:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2542
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[59] => WP_Post Object
(
[ID] => 2544
[post_author] => 5
[post_date] => 2021-03-12 14:16:06
[post_date_gmt] => 2021-03-12 14:16:06
[post_content] =>
[post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:25:14
[post_modified_gmt] => 2021-05-17 13:25:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2544
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[60] => WP_Post Object
(
[ID] => 2545
[post_author] => 5
[post_date] => 2021-03-12 14:14:38
[post_date_gmt] => 2021-03-12 14:14:38
[post_content] =>
[post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:25:23
[post_modified_gmt] => 2021-05-17 13:25:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2545
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[61] => WP_Post Object
(
[ID] => 2546
[post_author] => 5
[post_date] => 2021-03-12 14:13:16
[post_date_gmt] => 2021-03-12 14:13:16
[post_content] =>
[post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:25:35
[post_modified_gmt] => 2021-05-17 13:25:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2546
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[62] => WP_Post Object
(
[ID] => 2547
[post_author] => 5
[post_date] => 2021-03-12 13:58:55
[post_date_gmt] => 2021-03-12 13:58:55
[post_content] =>
[post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-21 10:39:30
[post_modified_gmt] => 2021-07-21 10:39:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2547
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[63] => WP_Post Object
(
[ID] => 2548
[post_author] => 5
[post_date] => 2021-03-12 13:55:59
[post_date_gmt] => 2021-03-12 13:55:59
[post_content] =>
[post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-04 09:42:06
[post_modified_gmt] => 2021-06-04 09:42:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2548
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[64] => WP_Post Object
(
[ID] => 2549
[post_author] => 5
[post_date] => 2021-03-12 13:50:41
[post_date_gmt] => 2021-03-12 13:50:41
[post_content] =>
[post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:25:58
[post_modified_gmt] => 2021-05-17 13:25:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2549
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[65] => WP_Post Object
(
[ID] => 2553
[post_author] => 5
[post_date] => 2021-03-12 13:47:42
[post_date_gmt] => 2021-03-12 13:47:42
[post_content] =>
[post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-28 16:09:05
[post_modified_gmt] => 2021-05-28 16:09:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2553
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[66] => WP_Post Object
(
[ID] => 2554
[post_author] => 5
[post_date] => 2021-03-12 13:44:47
[post_date_gmt] => 2021-03-12 13:44:47
[post_content] =>
[post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:26:22
[post_modified_gmt] => 2021-05-17 13:26:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2554
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[67] => WP_Post Object
(
[ID] => 2457
[post_author] => 5
[post_date] => 2021-02-25 15:25:57
[post_date_gmt] => 2021-02-25 15:25:57
[post_content] =>
[post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:09:35
[post_modified_gmt] => 2021-05-17 13:09:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2457
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[68] => WP_Post Object
(
[ID] => 2459
[post_author] => 5
[post_date] => 2021-02-25 15:25:31
[post_date_gmt] => 2021-02-25 15:25:31
[post_content] =>
[post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-01 09:50:06
[post_modified_gmt] => 2021-06-01 09:50:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2459
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[69] => WP_Post Object
(
[ID] => 2460
[post_author] => 5
[post_date] => 2021-02-25 15:23:51
[post_date_gmt] => 2021-02-25 15:23:51
[post_content] =>
[post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-02-25 15:23:51
[post_modified_gmt] => 2021-02-25 15:23:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2460
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[70] => WP_Post Object
(
[ID] => 2461
[post_author] => 5
[post_date] => 2021-02-25 15:23:35
[post_date_gmt] => 2021-02-25 15:23:35
[post_content] =>
[post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-02-25 15:23:35
[post_modified_gmt] => 2021-02-25 15:23:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2461
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[71] => WP_Post Object
(
[ID] => 2462
[post_author] => 5
[post_date] => 2021-02-25 15:23:19
[post_date_gmt] => 2021-02-25 15:23:19
[post_content] =>
[post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-02-25 15:23:19
[post_modified_gmt] => 2021-02-25 15:23:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2462
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[72] => WP_Post Object
(
[ID] => 2463
[post_author] => 5
[post_date] => 2021-02-25 15:22:52
[post_date_gmt] => 2021-02-25 15:22:52
[post_content] =>
[post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-01 09:55:43
[post_modified_gmt] => 2021-06-01 09:55:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2463
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[73] => WP_Post Object
(
[ID] => 2464
[post_author] => 5
[post_date] => 2021-02-25 15:21:51
[post_date_gmt] => 2021-02-25 15:21:51
[post_content] =>
[post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-02-25 15:21:51
[post_modified_gmt] => 2021-02-25 15:21:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2464
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[74] => WP_Post Object
(
[ID] => 2465
[post_author] => 5
[post_date] => 2021-02-25 15:21:32
[post_date_gmt] => 2021-02-25 15:21:32
[post_content] =>
[post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-27 10:25:45
[post_modified_gmt] => 2021-05-27 10:25:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2465
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[75] => WP_Post Object
(
[ID] => 2466
[post_author] => 5
[post_date] => 2021-02-25 15:20:40
[post_date_gmt] => 2021-02-25 15:20:40
[post_content] =>
[post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-21 14:59:57
[post_modified_gmt] => 2021-06-21 14:59:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2466
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[76] => WP_Post Object
(
[ID] => 2467
[post_author] => 5
[post_date] => 2021-02-25 15:20:15
[post_date_gmt] => 2021-02-25 15:20:15
[post_content] =>
[post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development
[to_ping] =>
[pinged] =>
[post_modified] => 2021-02-25 15:20:15
[post_modified_gmt] => 2021-02-25 15:20:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2467
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[77] => WP_Post Object
(
[ID] => 2470
[post_author] => 5
[post_date] => 2021-01-25 13:24:13
[post_date_gmt] => 2021-01-25 13:24:13
[post_content] =>
[post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:26:57
[post_modified_gmt] => 2021-05-17 13:26:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2470
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[78] => WP_Post Object
(
[ID] => 2472
[post_author] => 5
[post_date] => 2021-01-25 13:23:03
[post_date_gmt] => 2021-01-25 13:23:03
[post_content] =>
[post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:27:05
[post_modified_gmt] => 2021-05-17 13:27:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2472
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[79] => WP_Post Object
(
[ID] => 2473
[post_author] => 5
[post_date] => 2021-01-25 13:21:58
[post_date_gmt] => 2021-01-25 13:21:58
[post_content] =>
[post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:27:13
[post_modified_gmt] => 2021-05-17 13:27:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2473
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[80] => WP_Post Object
(
[ID] => 2474
[post_author] => 5
[post_date] => 2021-01-25 13:19:34
[post_date_gmt] => 2021-01-25 13:19:34
[post_content] =>
[post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-22 11:53:52
[post_modified_gmt] => 2021-07-22 11:53:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2474
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[81] => WP_Post Object
(
[ID] => 2475
[post_author] => 5
[post_date] => 2021-01-25 13:18:53
[post_date_gmt] => 2021-01-25 13:18:53
[post_content] =>
[post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:27:28
[post_modified_gmt] => 2021-05-17 13:27:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2475
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[82] => WP_Post Object
(
[ID] => 2476
[post_author] => 5
[post_date] => 2021-01-25 13:18:09
[post_date_gmt] => 2021-01-25 13:18:09
[post_content] =>
[post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:27:36
[post_modified_gmt] => 2021-05-17 13:27:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2476
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[83] => WP_Post Object
(
[ID] => 2477
[post_author] => 5
[post_date] => 2021-01-25 13:16:23
[post_date_gmt] => 2021-01-25 13:16:23
[post_content] =>
[post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:27:44
[post_modified_gmt] => 2021-05-17 13:27:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2477
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[84] => WP_Post Object
(
[ID] => 2478
[post_author] => 5
[post_date] => 2021-01-25 13:14:33
[post_date_gmt] => 2021-01-25 13:14:33
[post_content] =>
[post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-17 11:31:53
[post_modified_gmt] => 2021-06-17 11:31:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2478
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[85] => WP_Post Object
(
[ID] => 2479
[post_author] => 5
[post_date] => 2021-01-25 13:12:32
[post_date_gmt] => 2021-01-25 13:12:32
[post_content] =>
[post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-01 17:33:15
[post_modified_gmt] => 2021-06-01 17:33:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2479
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[86] => WP_Post Object
(
[ID] => 2480
[post_author] => 5
[post_date] => 2021-01-25 13:11:47
[post_date_gmt] => 2021-01-25 13:11:47
[post_content] =>
[post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:28:03
[post_modified_gmt] => 2021-05-17 13:28:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2480
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[87] => WP_Post Object
(
[ID] => 2481
[post_author] => 5
[post_date] => 2021-01-25 13:11:08
[post_date_gmt] => 2021-01-25 13:11:08
[post_content] =>
[post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-17 09:53:25
[post_modified_gmt] => 2021-06-17 09:53:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2481
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[88] => WP_Post Object
(
[ID] => 2482
[post_author] => 5
[post_date] => 2021-01-25 13:09:37
[post_date_gmt] => 2021-01-25 13:09:37
[post_content] =>
[post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-16 15:58:24
[post_modified_gmt] => 2021-06-16 15:58:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2482
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[89] => WP_Post Object
(
[ID] => 2483
[post_author] => 5
[post_date] => 2021-01-25 13:08:51
[post_date_gmt] => 2021-01-25 13:08:51
[post_content] =>
[post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:28:30
[post_modified_gmt] => 2021-05-17 13:28:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2483
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[90] => WP_Post Object
(
[ID] => 2471
[post_author] => 5
[post_date] => 2021-01-25 13:08:02
[post_date_gmt] => 2021-01-25 13:08:02
[post_content] =>
[post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-10 10:15:54
[post_modified_gmt] => 2021-06-10 10:15:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2471
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[91] => WP_Post Object
(
[ID] => 3406
[post_author] => 5
[post_date] => 2021-06-30 18:25:58
[post_date_gmt] => 2021-06-30 18:25:58
[post_content] =>
[post_title] => NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 18:26:40
[post_modified_gmt] => 2021-06-30 18:26:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3406
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[92] => WP_Post Object
(
[ID] => 3304
[post_author] => 6
[post_date] => 2021-06-30 09:30:56
[post_date_gmt] => 2021-06-30 09:30:56
[post_content] =>
[post_title] => UK Government – Roche, REGN-COV2 Supply Agreement for Pandemic Purposes
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 09:30:56
[post_modified_gmt] => 2021-06-30 09:30:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3304
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[93] => WP_Post Object
(
[ID] => 3127
[post_author] => 6
[post_date] => 2021-06-03 15:08:41
[post_date_gmt] => 2021-06-03 15:08:41
[post_content] =>
[post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-04 08:01:02
[post_modified_gmt] => 2021-06-04 08:01:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3127
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[94] => WP_Post Object
(
[ID] => 3126
[post_author] => 6
[post_date] => 2021-06-03 15:05:40
[post_date_gmt] => 2021-06-03 15:05:40
[post_content] =>
[post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-04 08:01:29
[post_modified_gmt] => 2021-06-04 08:01:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3126
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[95] => WP_Post Object
(
[ID] => 3125
[post_author] => 6
[post_date] => 2021-06-03 15:03:17
[post_date_gmt] => 2021-06-03 15:03:17
[post_content] =>
[post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-04 08:01:54
[post_modified_gmt] => 2021-06-04 08:01:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3125
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[96] => WP_Post Object
(
[ID] => 3124
[post_author] => 6
[post_date] => 2021-06-03 15:01:23
[post_date_gmt] => 2021-06-03 15:01:23
[post_content] =>
[post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-04 08:02:32
[post_modified_gmt] => 2021-06-04 08:02:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3124
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[97] => WP_Post Object
(
[ID] => 3123
[post_author] => 6
[post_date] => 2021-06-03 14:51:22
[post_date_gmt] => 2021-06-03 14:51:22
[post_content] =>
[post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-21 12:37:50
[post_modified_gmt] => 2021-07-21 12:37:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3123
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[98] => WP_Post Object
(
[ID] => 3122
[post_author] => 6
[post_date] => 2021-06-03 14:45:44
[post_date_gmt] => 2021-06-03 14:45:44
[post_content] =>
[post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-04 08:05:37
[post_modified_gmt] => 2021-06-04 08:05:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3122
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[99] => WP_Post Object
(
[ID] => 3121
[post_author] => 6
[post_date] => 2021-06-03 14:26:32
[post_date_gmt] => 2021-06-03 14:26:32
[post_content] =>
[post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-04 08:09:56
[post_modified_gmt] => 2021-06-04 08:09:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3121
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[100] => WP_Post Object
(
[ID] => 3120
[post_author] => 6
[post_date] => 2021-06-03 14:24:03
[post_date_gmt] => 2021-06-03 14:24:03
[post_content] =>
[post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-04 08:13:26
[post_modified_gmt] => 2021-06-04 08:13:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3120
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[101] => WP_Post Object
(
[ID] => 3119
[post_author] => 6
[post_date] => 2021-06-03 14:21:50
[post_date_gmt] => 2021-06-03 14:21:50
[post_content] =>
[post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-07 13:54:22
[post_modified_gmt] => 2021-06-07 13:54:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3119
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[102] => WP_Post Object
(
[ID] => 2947
[post_author] => 6
[post_date] => 2021-05-28 18:54:17
[post_date_gmt] => 2021-05-28 18:54:17
[post_content] =>
[post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-02 08:16:41
[post_modified_gmt] => 2021-06-02 08:16:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2947
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[103] => WP_Post Object
(
[ID] => 2873
[post_author] => 6
[post_date] => 2021-05-11 15:17:08
[post_date_gmt] => 2021-05-11 15:17:08
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-26 08:35:05
[post_modified_gmt] => 2021-05-26 08:35:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2873
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[104] => WP_Post Object
(
[ID] => 2872
[post_author] => 6
[post_date] => 2021-05-11 15:14:24
[post_date_gmt] => 2021-05-11 15:14:24
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-07 14:35:52
[post_modified_gmt] => 2021-06-07 14:35:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2872
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[105] => WP_Post Object
(
[ID] => 2870
[post_author] => 6
[post_date] => 2021-05-11 15:07:59
[post_date_gmt] => 2021-05-11 15:07:59
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-15 09:15:21
[post_modified_gmt] => 2021-06-15 09:15:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2870
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[106] => WP_Post Object
(
[ID] => 2869
[post_author] => 6
[post_date] => 2021-05-11 14:53:04
[post_date_gmt] => 2021-05-11 14:53:04
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-14 09:15:00
[post_modified_gmt] => 2021-05-14 09:15:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2869
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[107] => WP_Post Object
(
[ID] => 2868
[post_author] => 6
[post_date] => 2021-05-11 14:44:06
[post_date_gmt] => 2021-05-11 14:44:06
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-14 09:26:33
[post_modified_gmt] => 2021-05-14 09:26:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2868
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[108] => WP_Post Object
(
[ID] => 2867
[post_author] => 6
[post_date] => 2021-05-11 14:28:02
[post_date_gmt] => 2021-05-11 14:28:02
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => 2867
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-01 09:21:28
[post_modified_gmt] => 2021-06-01 09:21:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2867
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[109] => WP_Post Object
(
[ID] => 2865
[post_author] => 6
[post_date] => 2021-05-11 14:25:05
[post_date_gmt] => 2021-05-11 14:25:05
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-14 09:48:01
[post_modified_gmt] => 2021-05-14 09:48:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2865
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[110] => WP_Post Object
(
[ID] => 2824
[post_author] => 5
[post_date] => 2021-04-16 16:39:49
[post_date_gmt] => 2021-04-16 16:39:49
[post_content] =>
[post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-04-16 16:39:49
[post_modified_gmt] => 2021-04-16 16:39:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2824
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[111] => WP_Post Object
(
[ID] => 2823
[post_author] => 5
[post_date] => 2021-04-16 16:17:11
[post_date_gmt] => 2021-04-16 16:17:11
[post_content] =>
[post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-04-16 16:17:11
[post_modified_gmt] => 2021-04-16 16:17:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2823
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[112] => WP_Post Object
(
[ID] => 2822
[post_author] => 5
[post_date] => 2021-04-16 16:09:31
[post_date_gmt] => 2021-04-16 16:09:31
[post_content] =>
[post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-04-16 16:09:31
[post_modified_gmt] => 2021-04-16 16:09:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2822
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[113] => WP_Post Object
(
[ID] => 2454
[post_author] => 5
[post_date] => 2021-01-19 11:44:16
[post_date_gmt] => 2021-01-19 11:44:16
[post_content] =>
[post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-27 09:43:04
[post_modified_gmt] => 2021-05-27 09:43:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2454
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[114] => WP_Post Object
(
[ID] => 2452
[post_author] => 5
[post_date] => 2021-01-19 11:41:19
[post_date_gmt] => 2021-01-19 11:41:19
[post_content] =>
[post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-02 12:14:43
[post_modified_gmt] => 2021-06-02 12:14:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2452
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[115] => WP_Post Object
(
[ID] => 2450
[post_author] => 5
[post_date] => 2021-01-19 11:04:23
[post_date_gmt] => 2021-01-19 11:04:23
[post_content] =>
[post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-27 09:47:15
[post_modified_gmt] => 2021-05-27 09:47:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2450
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[116] => WP_Post Object
(
[ID] => 2449
[post_author] => 5
[post_date] => 2021-01-19 10:47:27
[post_date_gmt] => 2021-01-19 10:47:27
[post_content] =>
[post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-27 09:47:52
[post_modified_gmt] => 2021-05-27 09:47:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2449
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[117] => WP_Post Object
(
[ID] => 2448
[post_author] => 5
[post_date] => 2021-01-19 10:24:45
[post_date_gmt] => 2021-01-19 10:24:45
[post_content] =>
[post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-dod-supply-agreement-for-mrna-vaccine
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-27 09:49:00
[post_modified_gmt] => 2021-05-27 09:49:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2448
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[118] => WP_Post Object
(
[ID] => 2445
[post_author] => 5
[post_date] => 2021-01-19 09:31:14
[post_date_gmt] => 2021-01-19 09:31:14
[post_content] =>
[post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-07 08:28:27
[post_modified_gmt] => 2021-07-07 08:28:27
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2445
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[119] => WP_Post Object
(
[ID] => 2444
[post_author] => 5
[post_date] => 2021-01-19 09:27:20
[post_date_gmt] => 2021-01-19 09:27:20
[post_content] =>
[post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-27 09:33:58
[post_modified_gmt] => 2021-05-27 09:33:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2444
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[120] => WP_Post Object
(
[ID] => 2443
[post_author] => 5
[post_date] => 2021-01-19 09:14:03
[post_date_gmt] => 2021-01-19 09:14:03
[post_content] =>
[post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-27 09:34:37
[post_modified_gmt] => 2021-05-27 09:34:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2443
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[121] => WP_Post Object
(
[ID] => 2442
[post_author] => 5
[post_date] => 2021-01-19 06:56:32
[post_date_gmt] => 2021-01-19 06:56:32
[post_content] =>
[post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-07 08:30:33
[post_modified_gmt] => 2021-07-07 08:30:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2442
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[122] => WP_Post Object
(
[ID] => 2441
[post_author] => 5
[post_date] => 2021-01-19 06:48:04
[post_date_gmt] => 2021-01-19 06:48:04
[post_content] =>
[post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-27 09:36:53
[post_modified_gmt] => 2021-05-27 09:36:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2441
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[123] => WP_Post Object
(
[ID] => 2440
[post_author] => 5
[post_date] => 2021-01-19 06:45:33
[post_date_gmt] => 2021-01-19 06:45:33
[post_content] =>
[post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-contract-for-development-of-mrna-vaccine
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-27 09:37:25
[post_modified_gmt] => 2021-05-27 09:37:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2440
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[124] => WP_Post Object
(
[ID] => 2425
[post_author] => 5
[post_date] => 2020-12-14 15:02:33
[post_date_gmt] => 2020-12-14 15:02:33
[post_content] =>
[post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-01-22 12:13:42
[post_modified_gmt] => 2021-01-22 12:13:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2425
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[125] => WP_Post Object
(
[ID] => 2426
[post_author] => 5
[post_date] => 2020-12-14 15:02:08
[post_date_gmt] => 2020-12-14 15:02:08
[post_content] =>
[post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-01 18:47:49
[post_modified_gmt] => 2021-06-01 18:47:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2426
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[126] => WP_Post Object
(
[ID] => 2424
[post_author] => 5
[post_date] => 2020-12-14 15:01:40
[post_date_gmt] => 2020-12-14 15:01:40
[post_content] =>
[post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-09 08:18:09
[post_modified_gmt] => 2021-06-09 08:18:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2424
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[127] => WP_Post Object
(
[ID] => 2422
[post_author] => 5
[post_date] => 2020-12-14 14:59:29
[post_date_gmt] => 2020-12-14 14:59:29
[post_content] =>
[post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-21 11:33:16
[post_modified_gmt] => 2021-06-21 11:33:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2422
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 128
[current_post] => -1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 3436
[post_author] => 6
[post_date] => 2021-07-01 03:48:49
[post_date_gmt] => 2021-07-01 03:48:49
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-22 11:01:08
[post_modified_gmt] => 2021-07-22 11:01:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3436
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 128
[max_num_pages] => 0
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] => 1
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] => 1
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] =>
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] => 1
[query_vars_hash:WP_Query:private] => b1050dec43e5eb51fb39662feaeb2b86
[query_vars_changed:WP_Query:private] => 1
[thumbnails_cached] =>
[stopwords:WP_Query:private] => Array
(
[0] => about
[1] => an
[2] => are
[3] => as
[4] => at
[5] => be
[6] => by
[7] => com
[8] => for
[9] => from
[10] => how
[11] => in
[12] => is
[13] => it
[14] => of
[15] => on
[16] => or
[17] => that
[18] => the
[19] => this
[20] => to
[21] => was
[22] => what
[23] => when
[24] => where
[25] => who
[26] => will
[27] => with
[28] => www
)
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)
[provisions] => Array
(
[0] => WP_Post Object
(
[ID] => 3436
[post_author] => 6
[post_date] => 2021-07-01 03:48:49
[post_date_gmt] => 2021-07-01 03:48:49
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-22 11:01:08
[post_modified_gmt] => 2021-07-22 11:01:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3436
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 3435
[post_author] => 6
[post_date] => 2021-07-01 03:45:58
[post_date_gmt] => 2021-07-01 03:45:58
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-01 03:45:58
[post_modified_gmt] => 2021-07-01 03:45:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3435
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 3434
[post_author] => 6
[post_date] => 2021-07-01 03:44:18
[post_date_gmt] => 2021-07-01 03:44:18
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-01 03:44:18
[post_modified_gmt] => 2021-07-01 03:44:18
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3434
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 3433
[post_author] => 6
[post_date] => 2021-07-01 03:41:21
[post_date_gmt] => 2021-07-01 03:41:21
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-01 03:41:21
[post_modified_gmt] => 2021-07-01 03:41:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3433
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 3431
[post_author] => 6
[post_date] => 2021-07-01 03:38:49
[post_date_gmt] => 2021-07-01 03:38:49
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-01 03:38:49
[post_modified_gmt] => 2021-07-01 03:38:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3431
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[5] => WP_Post Object
(
[ID] => 3430
[post_author] => 6
[post_date] => 2021-07-01 03:27:51
[post_date_gmt] => 2021-07-01 03:27:51
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-22 13:58:20
[post_modified_gmt] => 2021-07-22 13:58:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3430
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[6] => WP_Post Object
(
[ID] => 3428
[post_author] => 6
[post_date] => 2021-07-01 03:24:00
[post_date_gmt] => 2021-07-01 03:24:00
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-01 03:24:00
[post_modified_gmt] => 2021-07-01 03:24:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3428
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[7] => WP_Post Object
(
[ID] => 3427
[post_author] => 6
[post_date] => 2021-07-01 03:22:23
[post_date_gmt] => 2021-07-01 03:22:23
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-01 03:22:23
[post_modified_gmt] => 2021-07-01 03:22:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3427
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[8] => WP_Post Object
(
[ID] => 3426
[post_author] => 6
[post_date] => 2021-07-01 03:06:23
[post_date_gmt] => 2021-07-01 03:06:23
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-01 03:06:23
[post_modified_gmt] => 2021-07-01 03:06:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3426
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[9] => WP_Post Object
(
[ID] => 3424
[post_author] => 6
[post_date] => 2021-07-01 03:03:57
[post_date_gmt] => 2021-07-01 03:03:57
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-01 03:03:57
[post_modified_gmt] => 2021-07-01 03:03:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3424
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[10] => WP_Post Object
(
[ID] => 3422
[post_author] => 6
[post_date] => 2021-07-01 02:58:21
[post_date_gmt] => 2021-07-01 02:58:21
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-22 15:32:57
[post_modified_gmt] => 2021-07-22 15:32:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3422
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[11] => WP_Post Object
(
[ID] => 3421
[post_author] => 6
[post_date] => 2021-07-01 02:56:30
[post_date_gmt] => 2021-07-01 02:56:30
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-01 02:56:30
[post_modified_gmt] => 2021-07-01 02:56:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3421
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[12] => WP_Post Object
(
[ID] => 3420
[post_author] => 6
[post_date] => 2021-07-01 02:52:05
[post_date_gmt] => 2021-07-01 02:52:05
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-01 02:52:05
[post_modified_gmt] => 2021-07-01 02:52:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3420
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[13] => WP_Post Object
(
[ID] => 3406
[post_author] => 5
[post_date] => 2021-06-30 18:25:58
[post_date_gmt] => 2021-06-30 18:25:58
[post_content] =>
[post_title] => NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 18:26:40
[post_modified_gmt] => 2021-06-30 18:26:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3406
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[14] => WP_Post Object
(
[ID] => 3372
[post_author] => 5
[post_date] => 2021-06-30 15:06:19
[post_date_gmt] => 2021-06-30 15:06:19
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 15:06:19
[post_modified_gmt] => 2021-06-30 15:06:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3372
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[15] => WP_Post Object
(
[ID] => 3371
[post_author] => 5
[post_date] => 2021-06-30 15:03:10
[post_date_gmt] => 2021-06-30 15:03:10
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 15:03:10
[post_modified_gmt] => 2021-06-30 15:03:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3371
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[16] => WP_Post Object
(
[ID] => 3370
[post_author] => 5
[post_date] => 2021-06-30 15:01:06
[post_date_gmt] => 2021-06-30 15:01:06
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 15:01:06
[post_modified_gmt] => 2021-06-30 15:01:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3370
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[17] => WP_Post Object
(
[ID] => 3368
[post_author] => 5
[post_date] => 2021-06-30 14:58:39
[post_date_gmt] => 2021-06-30 14:58:39
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 14:58:39
[post_modified_gmt] => 2021-06-30 14:58:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3368
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[18] => WP_Post Object
(
[ID] => 3366
[post_author] => 5
[post_date] => 2021-06-30 14:53:53
[post_date_gmt] => 2021-06-30 14:53:53
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 14:53:53
[post_modified_gmt] => 2021-06-30 14:53:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3366
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[19] => WP_Post Object
(
[ID] => 3364
[post_author] => 5
[post_date] => 2021-06-30 14:47:34
[post_date_gmt] => 2021-06-30 14:47:34
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 14:47:34
[post_modified_gmt] => 2021-06-30 14:47:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3364
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[20] => WP_Post Object
(
[ID] => 3363
[post_author] => 5
[post_date] => 2021-06-30 14:45:00
[post_date_gmt] => 2021-06-30 14:45:00
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 14:45:00
[post_modified_gmt] => 2021-06-30 14:45:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3363
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[21] => WP_Post Object
(
[ID] => 3361
[post_author] => 5
[post_date] => 2021-06-30 14:30:51
[post_date_gmt] => 2021-06-30 14:30:51
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 14:30:51
[post_modified_gmt] => 2021-06-30 14:30:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3361
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[22] => WP_Post Object
(
[ID] => 3360
[post_author] => 5
[post_date] => 2021-06-30 14:28:40
[post_date_gmt] => 2021-06-30 14:28:40
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 14:28:40
[post_modified_gmt] => 2021-06-30 14:28:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3360
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[23] => WP_Post Object
(
[ID] => 3356
[post_author] => 5
[post_date] => 2021-06-30 13:53:23
[post_date_gmt] => 2021-06-30 13:53:23
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 13:53:23
[post_modified_gmt] => 2021-06-30 13:53:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3356
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[24] => WP_Post Object
(
[ID] => 3354
[post_author] => 5
[post_date] => 2021-06-30 13:29:21
[post_date_gmt] => 2021-06-30 13:29:21
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 13:29:21
[post_modified_gmt] => 2021-06-30 13:29:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3354
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[25] => WP_Post Object
(
[ID] => 3352
[post_author] => 5
[post_date] => 2021-06-30 13:24:49
[post_date_gmt] => 2021-06-30 13:24:49
[post_content] =>
[post_title] => Natick Contracting Division - Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 13:24:49
[post_modified_gmt] => 2021-06-30 13:24:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3352
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[26] => WP_Post Object
(
[ID] => 3304
[post_author] => 6
[post_date] => 2021-06-30 09:30:56
[post_date_gmt] => 2021-06-30 09:30:56
[post_content] =>
[post_title] => UK Government – Roche, REGN-COV2 Supply Agreement for Pandemic Purposes
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 09:30:56
[post_modified_gmt] => 2021-06-30 09:30:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3304
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[27] => WP_Post Object
(
[ID] => 3221
[post_author] => 6
[post_date] => 2021-06-28 12:23:49
[post_date_gmt] => 2021-06-28 12:23:49
[post_content] =>
[post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-28 12:23:49
[post_modified_gmt] => 2021-06-28 12:23:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3221
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[28] => WP_Post Object
(
[ID] => 3220
[post_author] => 6
[post_date] => 2021-06-28 12:22:09
[post_date_gmt] => 2021-06-28 12:22:09
[post_content] =>
[post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-28 12:22:09
[post_modified_gmt] => 2021-06-28 12:22:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3220
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[29] => WP_Post Object
(
[ID] => 3219
[post_author] => 6
[post_date] => 2021-06-28 12:19:29
[post_date_gmt] => 2021-06-28 12:19:29
[post_content] =>
[post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-28 12:19:29
[post_modified_gmt] => 2021-06-28 12:19:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3219
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[30] => WP_Post Object
(
[ID] => 3218
[post_author] => 6
[post_date] => 2021-06-28 12:16:20
[post_date_gmt] => 2021-06-28 12:16:20
[post_content] =>
[post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-28 12:16:20
[post_modified_gmt] => 2021-06-28 12:16:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3218
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[31] => WP_Post Object
(
[ID] => 3217
[post_author] => 6
[post_date] => 2021-06-28 12:14:37
[post_date_gmt] => 2021-06-28 12:14:37
[post_content] =>
[post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-28 12:14:37
[post_modified_gmt] => 2021-06-28 12:14:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3217
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[32] => WP_Post Object
(
[ID] => 3216
[post_author] => 6
[post_date] => 2021-06-28 12:11:22
[post_date_gmt] => 2021-06-28 12:11:22
[post_content] =>
[post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-28 12:11:22
[post_modified_gmt] => 2021-06-28 12:11:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3216
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[33] => WP_Post Object
(
[ID] => 3215
[post_author] => 6
[post_date] => 2021-06-28 12:07:55
[post_date_gmt] => 2021-06-28 12:07:55
[post_content] =>
[post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-28 12:07:55
[post_modified_gmt] => 2021-06-28 12:07:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3215
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[34] => WP_Post Object
(
[ID] => 3127
[post_author] => 6
[post_date] => 2021-06-03 15:08:41
[post_date_gmt] => 2021-06-03 15:08:41
[post_content] =>
[post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-04 08:01:02
[post_modified_gmt] => 2021-06-04 08:01:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3127
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[35] => WP_Post Object
(
[ID] => 3126
[post_author] => 6
[post_date] => 2021-06-03 15:05:40
[post_date_gmt] => 2021-06-03 15:05:40
[post_content] =>
[post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-04 08:01:29
[post_modified_gmt] => 2021-06-04 08:01:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3126
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[36] => WP_Post Object
(
[ID] => 3125
[post_author] => 6
[post_date] => 2021-06-03 15:03:17
[post_date_gmt] => 2021-06-03 15:03:17
[post_content] =>
[post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-04 08:01:54
[post_modified_gmt] => 2021-06-04 08:01:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3125
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[37] => WP_Post Object
(
[ID] => 3124
[post_author] => 6
[post_date] => 2021-06-03 15:01:23
[post_date_gmt] => 2021-06-03 15:01:23
[post_content] =>
[post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-04 08:02:32
[post_modified_gmt] => 2021-06-04 08:02:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3124
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[38] => WP_Post Object
(
[ID] => 3123
[post_author] => 6
[post_date] => 2021-06-03 14:51:22
[post_date_gmt] => 2021-06-03 14:51:22
[post_content] =>
[post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-21 12:37:50
[post_modified_gmt] => 2021-07-21 12:37:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3123
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[39] => WP_Post Object
(
[ID] => 3122
[post_author] => 6
[post_date] => 2021-06-03 14:45:44
[post_date_gmt] => 2021-06-03 14:45:44
[post_content] =>
[post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-04 08:05:37
[post_modified_gmt] => 2021-06-04 08:05:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3122
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[40] => WP_Post Object
(
[ID] => 3121
[post_author] => 6
[post_date] => 2021-06-03 14:26:32
[post_date_gmt] => 2021-06-03 14:26:32
[post_content] =>
[post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-04 08:09:56
[post_modified_gmt] => 2021-06-04 08:09:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3121
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[41] => WP_Post Object
(
[ID] => 3120
[post_author] => 6
[post_date] => 2021-06-03 14:24:03
[post_date_gmt] => 2021-06-03 14:24:03
[post_content] =>
[post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-04 08:13:26
[post_modified_gmt] => 2021-06-04 08:13:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3120
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[42] => WP_Post Object
(
[ID] => 3119
[post_author] => 6
[post_date] => 2021-06-03 14:21:50
[post_date_gmt] => 2021-06-03 14:21:50
[post_content] =>
[post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-07 13:54:22
[post_modified_gmt] => 2021-06-07 13:54:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3119
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[43] => WP_Post Object
(
[ID] => 2956
[post_author] => 6
[post_date] => 2021-05-28 18:56:15
[post_date_gmt] => 2021-05-28 18:56:15
[post_content] =>
[post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-02 08:49:49
[post_modified_gmt] => 2021-06-02 08:49:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2956
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[44] => WP_Post Object
(
[ID] => 2961
[post_author] => 6
[post_date] => 2021-05-28 18:55:47
[post_date_gmt] => 2021-05-28 18:55:47
[post_content] =>
[post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-02 09:23:30
[post_modified_gmt] => 2021-06-02 09:23:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2961
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[45] => WP_Post Object
(
[ID] => 2965
[post_author] => 6
[post_date] => 2021-05-28 18:55:12
[post_date_gmt] => 2021-05-28 18:55:12
[post_content] =>
[post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-08 13:00:56
[post_modified_gmt] => 2021-06-08 13:00:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2965
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[46] => WP_Post Object
(
[ID] => 2947
[post_author] => 6
[post_date] => 2021-05-28 18:54:17
[post_date_gmt] => 2021-05-28 18:54:17
[post_content] =>
[post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-02 08:16:41
[post_modified_gmt] => 2021-06-02 08:16:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2947
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[47] => WP_Post Object
(
[ID] => 2960
[post_author] => 6
[post_date] => 2021-05-28 18:53:36
[post_date_gmt] => 2021-05-28 18:53:36
[post_content] =>
[post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-02 09:21:06
[post_modified_gmt] => 2021-06-02 09:21:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2960
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[48] => WP_Post Object
(
[ID] => 2964
[post_author] => 6
[post_date] => 2021-05-28 18:53:11
[post_date_gmt] => 2021-05-28 18:53:11
[post_content] =>
[post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-02 08:02:13
[post_modified_gmt] => 2021-06-02 08:02:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2964
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[49] => WP_Post Object
(
[ID] => 2958
[post_author] => 6
[post_date] => 2021-05-28 18:52:54
[post_date_gmt] => 2021-05-28 18:52:54
[post_content] =>
[post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-02 09:14:15
[post_modified_gmt] => 2021-06-02 09:14:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2958
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[50] => WP_Post Object
(
[ID] => 2949
[post_author] => 6
[post_date] => 2021-05-28 18:52:06
[post_date_gmt] => 2021-05-28 18:52:06
[post_content] =>
[post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-23 13:13:35
[post_modified_gmt] => 2021-06-23 13:13:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2949
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[51] => WP_Post Object
(
[ID] => 2957
[post_author] => 6
[post_date] => 2021-05-28 18:51:39
[post_date_gmt] => 2021-05-28 18:51:39
[post_content] =>
[post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-02 09:09:58
[post_modified_gmt] => 2021-06-02 09:09:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2957
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[52] => WP_Post Object
(
[ID] => 2962
[post_author] => 6
[post_date] => 2021-05-28 18:50:18
[post_date_gmt] => 2021-05-28 18:50:18
[post_content] =>
[post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-02 09:19:22
[post_modified_gmt] => 2021-06-02 09:19:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2962
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[53] => WP_Post Object
(
[ID] => 2945
[post_author] => 6
[post_date] => 2021-05-28 14:03:27
[post_date_gmt] => 2021-05-28 14:03:27
[post_content] =>
[post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-02 08:51:28
[post_modified_gmt] => 2021-06-02 08:51:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2945
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[54] => WP_Post Object
(
[ID] => 2909
[post_author] => 6
[post_date] => 2021-05-19 15:13:58
[post_date_gmt] => 2021-05-19 15:13:58
[post_content] =>
[post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-16 15:39:30
[post_modified_gmt] => 2021-06-16 15:39:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2909
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[55] => WP_Post Object
(
[ID] => 2908
[post_author] => 6
[post_date] => 2021-05-19 15:08:05
[post_date_gmt] => 2021-05-19 15:08:05
[post_content] =>
[post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-21 12:18:00
[post_modified_gmt] => 2021-07-21 12:18:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2908
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[56] => WP_Post Object
(
[ID] => 2907
[post_author] => 6
[post_date] => 2021-05-19 14:46:20
[post_date_gmt] => 2021-05-19 14:46:20
[post_content] =>
[post_title] => Novavax – CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-22 14:10:32
[post_modified_gmt] => 2021-07-22 14:10:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2907
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[57] => WP_Post Object
(
[ID] => 2893
[post_author] => 6
[post_date] => 2021-05-19 14:40:45
[post_date_gmt] => 2021-05-19 14:40:45
[post_content] =>
[post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-21 08:56:01
[post_modified_gmt] => 2021-06-21 08:56:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2893
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[58] => WP_Post Object
(
[ID] => 2892
[post_author] => 6
[post_date] => 2021-05-14 19:30:23
[post_date_gmt] => 2021-05-14 19:30:23
[post_content] =>
[post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-02 15:13:39
[post_modified_gmt] => 2021-06-02 15:13:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2892
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[59] => WP_Post Object
(
[ID] => 2890
[post_author] => 6
[post_date] => 2021-05-14 19:14:07
[post_date_gmt] => 2021-05-14 19:14:07
[post_content] =>
[post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-08 12:49:25
[post_modified_gmt] => 2021-06-08 12:49:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2890
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[60] => WP_Post Object
(
[ID] => 2889
[post_author] => 6
[post_date] => 2021-05-14 19:09:07
[post_date_gmt] => 2021-05-14 19:09:07
[post_content] =>
[post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-14 19:09:07
[post_modified_gmt] => 2021-05-14 19:09:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2889
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[61] => WP_Post Object
(
[ID] => 2888
[post_author] => 6
[post_date] => 2021-05-14 19:01:08
[post_date_gmt] => 2021-05-14 19:01:08
[post_content] =>
[post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-20 12:23:46
[post_modified_gmt] => 2021-05-20 12:23:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2888
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[62] => WP_Post Object
(
[ID] => 2886
[post_author] => 6
[post_date] => 2021-05-14 18:21:24
[post_date_gmt] => 2021-05-14 18:21:24
[post_content] =>
[post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-14 18:21:24
[post_modified_gmt] => 2021-05-14 18:21:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2886
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[63] => WP_Post Object
(
[ID] => 2885
[post_author] => 5
[post_date] => 2021-05-14 18:17:37
[post_date_gmt] => 2021-05-14 18:17:37
[post_content] =>
[post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-14 18:17:37
[post_modified_gmt] => 2021-05-14 18:17:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2885
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[64] => WP_Post Object
(
[ID] => 2873
[post_author] => 6
[post_date] => 2021-05-11 15:17:08
[post_date_gmt] => 2021-05-11 15:17:08
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-26 08:35:05
[post_modified_gmt] => 2021-05-26 08:35:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2873
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[65] => WP_Post Object
(
[ID] => 2872
[post_author] => 6
[post_date] => 2021-05-11 15:14:24
[post_date_gmt] => 2021-05-11 15:14:24
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-07 14:35:52
[post_modified_gmt] => 2021-06-07 14:35:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2872
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[66] => WP_Post Object
(
[ID] => 2870
[post_author] => 6
[post_date] => 2021-05-11 15:07:59
[post_date_gmt] => 2021-05-11 15:07:59
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-15 09:15:21
[post_modified_gmt] => 2021-06-15 09:15:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2870
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[67] => WP_Post Object
(
[ID] => 2869
[post_author] => 6
[post_date] => 2021-05-11 14:53:04
[post_date_gmt] => 2021-05-11 14:53:04
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-14 09:15:00
[post_modified_gmt] => 2021-05-14 09:15:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2869
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[68] => WP_Post Object
(
[ID] => 2868
[post_author] => 6
[post_date] => 2021-05-11 14:44:06
[post_date_gmt] => 2021-05-11 14:44:06
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-14 09:26:33
[post_modified_gmt] => 2021-05-14 09:26:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2868
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[69] => WP_Post Object
(
[ID] => 2867
[post_author] => 6
[post_date] => 2021-05-11 14:28:02
[post_date_gmt] => 2021-05-11 14:28:02
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => 2867
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-01 09:21:28
[post_modified_gmt] => 2021-06-01 09:21:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2867
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[70] => WP_Post Object
(
[ID] => 2865
[post_author] => 6
[post_date] => 2021-05-11 14:25:05
[post_date_gmt] => 2021-05-11 14:25:05
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-14 09:48:01
[post_modified_gmt] => 2021-05-14 09:48:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2865
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[71] => WP_Post Object
(
[ID] => 2824
[post_author] => 5
[post_date] => 2021-04-16 16:39:49
[post_date_gmt] => 2021-04-16 16:39:49
[post_content] =>
[post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-04-16 16:39:49
[post_modified_gmt] => 2021-04-16 16:39:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2824
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[72] => WP_Post Object
(
[ID] => 2823
[post_author] => 5
[post_date] => 2021-04-16 16:17:11
[post_date_gmt] => 2021-04-16 16:17:11
[post_content] =>
[post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-04-16 16:17:11
[post_modified_gmt] => 2021-04-16 16:17:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2823
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[73] => WP_Post Object
(
[ID] => 2822
[post_author] => 5
[post_date] => 2021-04-16 16:09:31
[post_date_gmt] => 2021-04-16 16:09:31
[post_content] =>
[post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-04-16 16:09:31
[post_modified_gmt] => 2021-04-16 16:09:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2822
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[74] => WP_Post Object
(
[ID] => 2821
[post_author] => 5
[post_date] => 2021-04-16 12:55:04
[post_date_gmt] => 2021-04-16 12:55:04
[post_content] =>
[post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-04-16 12:55:04
[post_modified_gmt] => 2021-04-16 12:55:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2821
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[75] => WP_Post Object
(
[ID] => 2820
[post_author] => 5
[post_date] => 2021-04-16 12:44:14
[post_date_gmt] => 2021-04-16 12:44:14
[post_content] =>
[post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-28 11:55:37
[post_modified_gmt] => 2021-05-28 11:55:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2820
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[76] => WP_Post Object
(
[ID] => 2819
[post_author] => 5
[post_date] => 2021-04-16 12:12:32
[post_date_gmt] => 2021-04-16 12:12:32
[post_content] =>
[post_title] => Regeneron - ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-04-16 12:15:57
[post_modified_gmt] => 2021-04-16 12:15:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2819
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[77] => WP_Post Object
(
[ID] => 2744
[post_author] => 5
[post_date] => 2021-03-30 15:12:35
[post_date_gmt] => 2021-03-30 15:12:35
[post_content] =>
[post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:21:21
[post_modified_gmt] => 2021-05-17 13:21:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2744
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[78] => WP_Post Object
(
[ID] => 2749
[post_author] => 5
[post_date] => 2021-03-30 15:10:16
[post_date_gmt] => 2021-03-30 15:10:16
[post_content] =>
[post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-01 09:43:25
[post_modified_gmt] => 2021-06-01 09:43:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2749
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[79] => WP_Post Object
(
[ID] => 2748
[post_author] => 5
[post_date] => 2021-03-30 15:05:46
[post_date_gmt] => 2021-03-30 15:05:46
[post_content] =>
[post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => 2748
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:21:40
[post_modified_gmt] => 2021-05-17 13:21:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2748
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[80] => WP_Post Object
(
[ID] => 2740
[post_author] => 5
[post_date] => 2021-03-30 14:54:54
[post_date_gmt] => 2021-03-30 14:54:54
[post_content] =>
[post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:21:50
[post_modified_gmt] => 2021-05-17 13:21:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2740
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[81] => WP_Post Object
(
[ID] => 2743
[post_author] => 5
[post_date] => 2021-03-24 15:11:40
[post_date_gmt] => 2021-03-24 15:11:40
[post_content] =>
[post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:22:13
[post_modified_gmt] => 2021-05-17 13:22:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2743
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[82] => WP_Post Object
(
[ID] => 2742
[post_author] => 5
[post_date] => 2021-03-24 13:37:07
[post_date_gmt] => 2021-03-24 13:37:07
[post_content] =>
[post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-22 14:14:47
[post_modified_gmt] => 2021-07-22 14:14:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2742
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[83] => WP_Post Object
(
[ID] => 2741
[post_author] => 5
[post_date] => 2021-03-24 13:32:55
[post_date_gmt] => 2021-03-24 13:32:55
[post_content] =>
[post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:22:24
[post_modified_gmt] => 2021-05-17 13:22:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2741
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[84] => WP_Post Object
(
[ID] => 2739
[post_author] => 5
[post_date] => 2021-03-24 13:12:14
[post_date_gmt] => 2021-03-24 13:12:14
[post_content] =>
[post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:22:33
[post_modified_gmt] => 2021-05-17 13:22:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2739
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[85] => WP_Post Object
(
[ID] => 2738
[post_author] => 5
[post_date] => 2021-03-24 13:04:24
[post_date_gmt] => 2021-03-24 13:04:24
[post_content] =>
[post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-09 09:03:59
[post_modified_gmt] => 2021-06-09 09:03:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2738
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[86] => WP_Post Object
(
[ID] => 2737
[post_author] => 5
[post_date] => 2021-03-24 13:00:46
[post_date_gmt] => 2021-03-24 13:00:46
[post_content] =>
[post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:23:04
[post_modified_gmt] => 2021-05-17 13:23:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2737
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[87] => WP_Post Object
(
[ID] => 2736
[post_author] => 5
[post_date] => 2021-03-23 18:15:15
[post_date_gmt] => 2021-03-23 18:15:15
[post_content] =>
[post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:23:17
[post_modified_gmt] => 2021-05-17 13:23:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2736
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[88] => WP_Post Object
(
[ID] => 2735
[post_author] => 5
[post_date] => 2021-03-23 18:05:28
[post_date_gmt] => 2021-03-23 18:05:28
[post_content] =>
[post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:23:28
[post_modified_gmt] => 2021-05-17 13:23:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2735
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[89] => WP_Post Object
(
[ID] => 2734
[post_author] => 5
[post_date] => 2021-03-23 18:01:22
[post_date_gmt] => 2021-03-23 18:01:22
[post_content] =>
[post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-07 17:12:58
[post_modified_gmt] => 2021-06-07 17:12:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2734
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[90] => WP_Post Object
(
[ID] => 2543
[post_author] => 5
[post_date] => 2021-03-12 18:15:58
[post_date_gmt] => 2021-03-12 18:15:58
[post_content] =>
[post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:24:40
[post_modified_gmt] => 2021-05-17 13:24:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2543
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[91] => WP_Post Object
(
[ID] => 2540
[post_author] => 5
[post_date] => 2021-03-12 18:12:48
[post_date_gmt] => 2021-03-12 18:12:48
[post_content] =>
[post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-07 13:52:44
[post_modified_gmt] => 2021-07-07 13:52:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2540
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[92] => WP_Post Object
(
[ID] => 2541
[post_author] => 5
[post_date] => 2021-03-12 18:11:14
[post_date_gmt] => 2021-03-12 18:11:14
[post_content] =>
[post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-28 16:06:34
[post_modified_gmt] => 2021-05-28 16:06:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2541
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[93] => WP_Post Object
(
[ID] => 2542
[post_author] => 5
[post_date] => 2021-03-12 14:21:07
[post_date_gmt] => 2021-03-12 14:21:07
[post_content] =>
[post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-28 15:59:01
[post_modified_gmt] => 2021-05-28 15:59:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2542
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[94] => WP_Post Object
(
[ID] => 2544
[post_author] => 5
[post_date] => 2021-03-12 14:16:06
[post_date_gmt] => 2021-03-12 14:16:06
[post_content] =>
[post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:25:14
[post_modified_gmt] => 2021-05-17 13:25:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2544
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[95] => WP_Post Object
(
[ID] => 2545
[post_author] => 5
[post_date] => 2021-03-12 14:14:38
[post_date_gmt] => 2021-03-12 14:14:38
[post_content] =>
[post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:25:23
[post_modified_gmt] => 2021-05-17 13:25:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2545
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[96] => WP_Post Object
(
[ID] => 2546
[post_author] => 5
[post_date] => 2021-03-12 14:13:16
[post_date_gmt] => 2021-03-12 14:13:16
[post_content] =>
[post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:25:35
[post_modified_gmt] => 2021-05-17 13:25:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2546
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[97] => WP_Post Object
(
[ID] => 2547
[post_author] => 5
[post_date] => 2021-03-12 13:58:55
[post_date_gmt] => 2021-03-12 13:58:55
[post_content] =>
[post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-21 10:39:30
[post_modified_gmt] => 2021-07-21 10:39:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2547
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[98] => WP_Post Object
(
[ID] => 2548
[post_author] => 5
[post_date] => 2021-03-12 13:55:59
[post_date_gmt] => 2021-03-12 13:55:59
[post_content] =>
[post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-04 09:42:06
[post_modified_gmt] => 2021-06-04 09:42:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2548
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[99] => WP_Post Object
(
[ID] => 2549
[post_author] => 5
[post_date] => 2021-03-12 13:50:41
[post_date_gmt] => 2021-03-12 13:50:41
[post_content] =>
[post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:25:58
[post_modified_gmt] => 2021-05-17 13:25:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2549
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[100] => WP_Post Object
(
[ID] => 2553
[post_author] => 5
[post_date] => 2021-03-12 13:47:42
[post_date_gmt] => 2021-03-12 13:47:42
[post_content] =>
[post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-28 16:09:05
[post_modified_gmt] => 2021-05-28 16:09:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2553
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[101] => WP_Post Object
(
[ID] => 2554
[post_author] => 5
[post_date] => 2021-03-12 13:44:47
[post_date_gmt] => 2021-03-12 13:44:47
[post_content] =>
[post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:26:22
[post_modified_gmt] => 2021-05-17 13:26:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2554
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[102] => WP_Post Object
(
[ID] => 2457
[post_author] => 5
[post_date] => 2021-02-25 15:25:57
[post_date_gmt] => 2021-02-25 15:25:57
[post_content] =>
[post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:09:35
[post_modified_gmt] => 2021-05-17 13:09:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2457
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[103] => WP_Post Object
(
[ID] => 2459
[post_author] => 5
[post_date] => 2021-02-25 15:25:31
[post_date_gmt] => 2021-02-25 15:25:31
[post_content] =>
[post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-01 09:50:06
[post_modified_gmt] => 2021-06-01 09:50:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2459
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[104] => WP_Post Object
(
[ID] => 2460
[post_author] => 5
[post_date] => 2021-02-25 15:23:51
[post_date_gmt] => 2021-02-25 15:23:51
[post_content] =>
[post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-02-25 15:23:51
[post_modified_gmt] => 2021-02-25 15:23:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2460
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[105] => WP_Post Object
(
[ID] => 2461
[post_author] => 5
[post_date] => 2021-02-25 15:23:35
[post_date_gmt] => 2021-02-25 15:23:35
[post_content] =>
[post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-02-25 15:23:35
[post_modified_gmt] => 2021-02-25 15:23:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2461
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[106] => WP_Post Object
(
[ID] => 2462
[post_author] => 5
[post_date] => 2021-02-25 15:23:19
[post_date_gmt] => 2021-02-25 15:23:19
[post_content] =>
[post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-02-25 15:23:19
[post_modified_gmt] => 2021-02-25 15:23:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2462
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[107] => WP_Post Object
(
[ID] => 2463
[post_author] => 5
[post_date] => 2021-02-25 15:22:52
[post_date_gmt] => 2021-02-25 15:22:52
[post_content] =>
[post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-01 09:55:43
[post_modified_gmt] => 2021-06-01 09:55:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2463
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[108] => WP_Post Object
(
[ID] => 2464
[post_author] => 5
[post_date] => 2021-02-25 15:21:51
[post_date_gmt] => 2021-02-25 15:21:51
[post_content] =>
[post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-02-25 15:21:51
[post_modified_gmt] => 2021-02-25 15:21:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2464
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[109] => WP_Post Object
(
[ID] => 2465
[post_author] => 5
[post_date] => 2021-02-25 15:21:32
[post_date_gmt] => 2021-02-25 15:21:32
[post_content] =>
[post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-27 10:25:45
[post_modified_gmt] => 2021-05-27 10:25:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2465
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[110] => WP_Post Object
(
[ID] => 2466
[post_author] => 5
[post_date] => 2021-02-25 15:20:40
[post_date_gmt] => 2021-02-25 15:20:40
[post_content] =>
[post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-21 14:59:57
[post_modified_gmt] => 2021-06-21 14:59:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2466
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[111] => WP_Post Object
(
[ID] => 2467
[post_author] => 5
[post_date] => 2021-02-25 15:20:15
[post_date_gmt] => 2021-02-25 15:20:15
[post_content] =>
[post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development
[to_ping] =>
[pinged] =>
[post_modified] => 2021-02-25 15:20:15
[post_modified_gmt] => 2021-02-25 15:20:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2467
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[112] => WP_Post Object
(
[ID] => 2470
[post_author] => 5
[post_date] => 2021-01-25 13:24:13
[post_date_gmt] => 2021-01-25 13:24:13
[post_content] =>
[post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:26:57
[post_modified_gmt] => 2021-05-17 13:26:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2470
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[113] => WP_Post Object
(
[ID] => 2472
[post_author] => 5
[post_date] => 2021-01-25 13:23:03
[post_date_gmt] => 2021-01-25 13:23:03
[post_content] =>
[post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:27:05
[post_modified_gmt] => 2021-05-17 13:27:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2472
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[114] => WP_Post Object
(
[ID] => 2473
[post_author] => 5
[post_date] => 2021-01-25 13:21:58
[post_date_gmt] => 2021-01-25 13:21:58
[post_content] =>
[post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:27:13
[post_modified_gmt] => 2021-05-17 13:27:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2473
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[115] => WP_Post Object
(
[ID] => 2474
[post_author] => 5
[post_date] => 2021-01-25 13:19:34
[post_date_gmt] => 2021-01-25 13:19:34
[post_content] =>
[post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-22 11:53:52
[post_modified_gmt] => 2021-07-22 11:53:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2474
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[116] => WP_Post Object
(
[ID] => 2475
[post_author] => 5
[post_date] => 2021-01-25 13:18:53
[post_date_gmt] => 2021-01-25 13:18:53
[post_content] =>
[post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:27:28
[post_modified_gmt] => 2021-05-17 13:27:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2475
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[117] => WP_Post Object
(
[ID] => 2476
[post_author] => 5
[post_date] => 2021-01-25 13:18:09
[post_date_gmt] => 2021-01-25 13:18:09
[post_content] =>
[post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:27:36
[post_modified_gmt] => 2021-05-17 13:27:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2476
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[118] => WP_Post Object
(
[ID] => 2477
[post_author] => 5
[post_date] => 2021-01-25 13:16:23
[post_date_gmt] => 2021-01-25 13:16:23
[post_content] =>
[post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:27:44
[post_modified_gmt] => 2021-05-17 13:27:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2477
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[119] => WP_Post Object
(
[ID] => 2478
[post_author] => 5
[post_date] => 2021-01-25 13:14:33
[post_date_gmt] => 2021-01-25 13:14:33
[post_content] =>
[post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-17 11:31:53
[post_modified_gmt] => 2021-06-17 11:31:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2478
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[120] => WP_Post Object
(
[ID] => 2479
[post_author] => 5
[post_date] => 2021-01-25 13:12:32
[post_date_gmt] => 2021-01-25 13:12:32
[post_content] =>
[post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-01 17:33:15
[post_modified_gmt] => 2021-06-01 17:33:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2479
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[121] => WP_Post Object
(
[ID] => 2480
[post_author] => 5
[post_date] => 2021-01-25 13:11:47
[post_date_gmt] => 2021-01-25 13:11:47
[post_content] =>
[post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:28:03
[post_modified_gmt] => 2021-05-17 13:28:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2480
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[122] => WP_Post Object
(
[ID] => 2481
[post_author] => 5
[post_date] => 2021-01-25 13:11:08
[post_date_gmt] => 2021-01-25 13:11:08
[post_content] =>
[post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-17 09:53:25
[post_modified_gmt] => 2021-06-17 09:53:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2481
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[123] => WP_Post Object
(
[ID] => 2482
[post_author] => 5
[post_date] => 2021-01-25 13:09:37
[post_date_gmt] => 2021-01-25 13:09:37
[post_content] =>
[post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-16 15:58:24
[post_modified_gmt] => 2021-06-16 15:58:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2482
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[124] => WP_Post Object
(
[ID] => 2483
[post_author] => 5
[post_date] => 2021-01-25 13:08:51
[post_date_gmt] => 2021-01-25 13:08:51
[post_content] =>
[post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-17 13:28:30
[post_modified_gmt] => 2021-05-17 13:28:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2483
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[125] => WP_Post Object
(
[ID] => 2471
[post_author] => 5
[post_date] => 2021-01-25 13:08:02
[post_date_gmt] => 2021-01-25 13:08:02
[post_content] =>
[post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-10 10:15:54
[post_modified_gmt] => 2021-06-10 10:15:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2471
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[126] => WP_Post Object
(
[ID] => 2454
[post_author] => 5
[post_date] => 2021-01-19 11:44:16
[post_date_gmt] => 2021-01-19 11:44:16
[post_content] =>
[post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-27 09:43:04
[post_modified_gmt] => 2021-05-27 09:43:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2454
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[127] => WP_Post Object
(
[ID] => 2452
[post_author] => 5
[post_date] => 2021-01-19 11:41:19
[post_date_gmt] => 2021-01-19 11:41:19
[post_content] =>
[post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-02 12:14:43
[post_modified_gmt] => 2021-06-02 12:14:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2452
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[128] => WP_Post Object
(
[ID] => 2450
[post_author] => 5
[post_date] => 2021-01-19 11:04:23
[post_date_gmt] => 2021-01-19 11:04:23
[post_content] =>
[post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-27 09:47:15
[post_modified_gmt] => 2021-05-27 09:47:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2450
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[129] => WP_Post Object
(
[ID] => 2449
[post_author] => 5
[post_date] => 2021-01-19 10:47:27
[post_date_gmt] => 2021-01-19 10:47:27
[post_content] =>
[post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-27 09:47:52
[post_modified_gmt] => 2021-05-27 09:47:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2449
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[130] => WP_Post Object
(
[ID] => 2448
[post_author] => 5
[post_date] => 2021-01-19 10:24:45
[post_date_gmt] => 2021-01-19 10:24:45
[post_content] =>
[post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-dod-supply-agreement-for-mrna-vaccine
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-27 09:49:00
[post_modified_gmt] => 2021-05-27 09:49:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2448
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[131] => WP_Post Object
(
[ID] => 2445
[post_author] => 5
[post_date] => 2021-01-19 09:31:14
[post_date_gmt] => 2021-01-19 09:31:14
[post_content] =>
[post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-07 08:28:27
[post_modified_gmt] => 2021-07-07 08:28:27
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2445
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[132] => WP_Post Object
(
[ID] => 2444
[post_author] => 5
[post_date] => 2021-01-19 09:27:20
[post_date_gmt] => 2021-01-19 09:27:20
[post_content] =>
[post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-27 09:33:58
[post_modified_gmt] => 2021-05-27 09:33:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2444
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[133] => WP_Post Object
(
[ID] => 2443
[post_author] => 5
[post_date] => 2021-01-19 09:14:03
[post_date_gmt] => 2021-01-19 09:14:03
[post_content] =>
[post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-27 09:34:37
[post_modified_gmt] => 2021-05-27 09:34:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2443
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[134] => WP_Post Object
(
[ID] => 2442
[post_author] => 5
[post_date] => 2021-01-19 06:56:32
[post_date_gmt] => 2021-01-19 06:56:32
[post_content] =>
[post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-07 08:30:33
[post_modified_gmt] => 2021-07-07 08:30:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2442
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[135] => WP_Post Object
(
[ID] => 2441
[post_author] => 5
[post_date] => 2021-01-19 06:48:04
[post_date_gmt] => 2021-01-19 06:48:04
[post_content] =>
[post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-27 09:36:53
[post_modified_gmt] => 2021-05-27 09:36:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2441
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[136] => WP_Post Object
(
[ID] => 2440
[post_author] => 5
[post_date] => 2021-01-19 06:45:33
[post_date_gmt] => 2021-01-19 06:45:33
[post_content] =>
[post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-contract-for-development-of-mrna-vaccine
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-27 09:37:25
[post_modified_gmt] => 2021-05-27 09:37:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2440
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[137] => WP_Post Object
(
[ID] => 2425
[post_author] => 5
[post_date] => 2020-12-14 15:02:33
[post_date_gmt] => 2020-12-14 15:02:33
[post_content] =>
[post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-01-22 12:13:42
[post_modified_gmt] => 2021-01-22 12:13:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2425
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[138] => WP_Post Object
(
[ID] => 2426
[post_author] => 5
[post_date] => 2020-12-14 15:02:08
[post_date_gmt] => 2020-12-14 15:02:08
[post_content] =>
[post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-01 18:47:49
[post_modified_gmt] => 2021-06-01 18:47:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2426
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[139] => WP_Post Object
(
[ID] => 2424
[post_author] => 5
[post_date] => 2020-12-14 15:01:40
[post_date_gmt] => 2020-12-14 15:01:40
[post_content] =>
[post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-09 08:18:09
[post_modified_gmt] => 2021-06-09 08:18:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2424
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[140] => WP_Post Object
(
[ID] => 2422
[post_author] => 5
[post_date] => 2020-12-14 14:59:29
[post_date_gmt] => 2020-12-14 14:59:29
[post_content] =>
[post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-21 11:33:16
[post_modified_gmt] => 2021-06-21 11:33:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2422
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[invalid_get] =>
[is_text_search] => 1
[has_agreement_filters] =>
[has_any_agreement_filter] => Array
(
)
[found_agreements] =>
[has_provision_filters] =>
[found_provisions] => 1
[lbl_quick_search:GHIAA2019\MapguideSearch:private] => Search results for:
[lbl_issue:GHIAA2019\MapguideSearch:private] => Issue:
[lbl_key_term:GHIAA2019\MapguideSearch:private] => Key Term:
[lbl_partner_type:GHIAA2019\MapguideSearch:private] => Partner Type:
[lbl_technology:GHIAA2019\MapguideSearch:private] => Technology:
[lbl_development_stage:GHIAA2019\MapguideSearch:private] => Development Stage:
[issues_by_id:GHIAA2019\MapguideSearch:private] => Array
(
[46] => WP_Term Object
(
[term_id] => 46
[name] => Access to medicines
[slug] => access-to-medicines
[term_group] => 0
[term_taxonomy_id] => 46
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[91] => WP_Term Object
(
[term_id] => 91
[name] => Access to results
[slug] => access-results
[term_group] => 0
[term_taxonomy_id] => 91
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 16
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[100] => WP_Term Object
(
[term_id] => 100
[name] => Affordable or reasonable pricing
[slug] => pricing
[term_group] => 0
[term_taxonomy_id] => 100
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 5
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[55] => WP_Term Object
(
[term_id] => 55
[name] => Annexes
[slug] => annexes
[term_group] => 0
[term_taxonomy_id] => 55
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[66] => WP_Term Object
(
[term_id] => 66
[name] => Benefit/revenue sharing
[slug] => benefit-revenue-sharing
[term_group] => 0
[term_taxonomy_id] => 66
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 4
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[53] => WP_Term Object
(
[term_id] => 53
[name] => Business model
[slug] => business-model
[term_group] => 0
[term_taxonomy_id] => 53
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 1
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[58] => WP_Term Object
(
[term_id] => 58
[name] => Commercialization strategy
[slug] => commercialization-strategy
[term_group] => 0
[term_taxonomy_id] => 58
[taxonomy] => issue
[description] =>
[parent] => 55
[count] => 0
[filter] => raw
[parent_name] => Annexes
[parent_slug] => annexes
)
[84] => WP_Term Object
(
[term_id] => 84
[name] => Confidentiality
[slug] => confidentiality
[term_group] => 0
[term_taxonomy_id] => 84
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 33
[filter] => raw
[parent_name] => Information sharing & data safety
[parent_slug] => information-sharing
)
[59] => WP_Term Object
(
[term_id] => 59
[name] => Conflict of Interest
[slug] => conflict-of-interest
[term_group] => 0
[term_taxonomy_id] => 59
[taxonomy] => issue
[description] =>
[parent] => 54
[count] => 2
[filter] => raw
[parent_name] => Other
[parent_slug] => other
)
[51] => WP_Term Object
(
[term_id] => 51
[name] => Consortium structure & management
[slug] => consortium-structure
[term_group] => 0
[term_taxonomy_id] => 51
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 9
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[82] => WP_Term Object
(
[term_id] => 82
[name] => Data management
[slug] => data-management
[term_group] => 0
[term_taxonomy_id] => 82
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 11
[filter] => raw
[parent_name] => Information sharing & data safety
[parent_slug] => information-sharing
)
[267] => WP_Term Object
(
[term_id] => 267
[name] => Dispute resolution
[slug] => dispute-resolution
[term_group] => 0
[term_taxonomy_id] => 267
[taxonomy] => issue
[description] =>
[parent] => 54
[count] => 10
[filter] => raw
[parent_name] => Other
[parent_slug] => other
)
[271] => WP_Term Object
(
[term_id] => 271
[name] => Donation
[slug] => donation
[term_group] => 0
[term_taxonomy_id] => 271
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 5
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[72] => WP_Term Object
(
[term_id] => 72
[name] => Effect of termination
[slug] => effect-of-termination
[term_group] => 0
[term_taxonomy_id] => 72
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 10
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[101] => WP_Term Object
(
[term_id] => 101
[name] => Equitable access
[slug] => equitable-access
[term_group] => 0
[term_taxonomy_id] => 101
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 8
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[83] => WP_Term Object
(
[term_id] => 83
[name] => Exceptions and limitations to the confidentiality obligations
[slug] => exceptions-confidentiality
[term_group] => 0
[term_taxonomy_id] => 83
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 8
[filter] => raw
[parent_name] => Information sharing & data safety
[parent_slug] => information-sharing
)
[93] => WP_Term Object
(
[term_id] => 93
[name] => Exceptions or limitations to the IP ownership rules
[slug] => exceptions-ip-ownership
[term_group] => 0
[term_taxonomy_id] => 93
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 2
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[92] => WP_Term Object
(
[term_id] => 92
[name] => Exploitation of results
[slug] => exploitation-results
[term_group] => 0
[term_taxonomy_id] => 92
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 13
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[103] => WP_Term Object
(
[term_id] => 103
[name] => Funder step-in rights
[slug] => funder-step-in
[term_group] => 0
[term_taxonomy_id] => 103
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 1
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[57] => WP_Term Object
(
[term_id] => 57
[name] => Global access plans
[slug] => global-access-plans
[term_group] => 0
[term_taxonomy_id] => 57
[taxonomy] => issue
[description] =>
[parent] => 55
[count] => 0
[filter] => raw
[parent_name] => Annexes
[parent_slug] => annexes
)
[80] => WP_Term Object
(
[term_id] => 80
[name] => Indemnity / indemnification
[slug] => indemnity
[term_group] => 0
[term_taxonomy_id] => 80
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 17
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[257] => WP_Term Object
(
[term_id] => 257
[name] => Information sharing
[slug] => information-sharing-information-sharing
[term_group] => 0
[term_taxonomy_id] => 257
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 16
[filter] => raw
[parent_name] => Information sharing & data safety
[parent_slug] => information-sharing
)
[49] => WP_Term Object
(
[term_id] => 49
[name] => Information sharing & data safety
[slug] => information-sharing
[term_group] => 0
[term_taxonomy_id] => 49
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[109] => WP_Term Object
(
[term_id] => 109
[name] => Insurance
[slug] => insurance
[term_group] => 0
[term_taxonomy_id] => 109
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 6
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[48] => WP_Term Object
(
[term_id] => 48
[name] => IP ownership & licensing
[slug] => ip-ownership
[term_group] => 0
[term_taxonomy_id] => 48
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[50] => WP_Term Object
(
[term_id] => 50
[name] => Liability
[slug] => liability
[term_group] => 0
[term_taxonomy_id] => 50
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[79] => WP_Term Object
(
[term_id] => 79
[name] => Limitation of liability/damage
[slug] => limitation-of-liability
[term_group] => 0
[term_taxonomy_id] => 79
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 23
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[85] => WP_Term Object
(
[term_id] => 85
[name] => Material transfer
[slug] => material-transfer
[term_group] => 0
[term_taxonomy_id] => 85
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 4
[filter] => raw
[parent_name] => Information sharing & data safety
[parent_slug] => information-sharing
)
[98] => WP_Term Object
(
[term_id] => 98
[name] => Open data
[slug] => open-data
[term_group] => 0
[term_taxonomy_id] => 98
[taxonomy] => issue
[description] =>
[parent] => 47
[count] => 10
[filter] => raw
[parent_name] => Open sciences & open data
[parent_slug] => open-science
)
[97] => WP_Term Object
(
[term_id] => 97
[name] => Open sciences
[slug] => open-sciences
[term_group] => 0
[term_taxonomy_id] => 97
[taxonomy] => issue
[description] =>
[parent] => 47
[count] => 8
[filter] => raw
[parent_name] => Open sciences & open data
[parent_slug] => open-science
)
[47] => WP_Term Object
(
[term_id] => 47
[name] => Open sciences & open data
[slug] => open-science
[term_group] => 0
[term_taxonomy_id] => 47
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[54] => WP_Term Object
(
[term_id] => 54
[name] => Other
[slug] => other
[term_group] => 0
[term_taxonomy_id] => 54
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[102] => WP_Term Object
(
[term_id] => 102
[name] => Outbreak preparedness
[slug] => outbreak-preparedness
[term_group] => 0
[term_taxonomy_id] => 102
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 4
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[87] => WP_Term Object
(
[term_id] => 87
[name] => Ownership of background IP
[slug] => ownership-background-ip
[term_group] => 0
[term_taxonomy_id] => 87
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 17
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[89] => WP_Term Object
(
[term_id] => 89
[name] => Ownership of results
[slug] => ownership-results
[term_group] => 0
[term_taxonomy_id] => 89
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 29
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[266] => WP_Term Object
(
[term_id] => 266
[name] => Pandemic Products
[slug] => pandemic-products
[term_group] => 0
[term_taxonomy_id] => 266
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 6
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[70] => WP_Term Object
(
[term_id] => 70
[name] => Payment Structures
[slug] => royalties-and-payments
[term_group] => 0
[term_taxonomy_id] => 70
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 14
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[90] => WP_Term Object
(
[term_id] => 90
[name] => Protection of results
[slug] => protection-results
[term_group] => 0
[term_taxonomy_id] => 90
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 16
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[107] => WP_Term Object
(
[term_id] => 107
[name] => Public health licenses
[slug] => public-health-licenses
[term_group] => 0
[term_taxonomy_id] => 107
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 5
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[96] => WP_Term Object
(
[term_id] => 96
[name] => Publication
[slug] => publication
[term_group] => 0
[term_taxonomy_id] => 96
[taxonomy] => issue
[description] =>
[parent] => 47
[count] => 13
[filter] => raw
[parent_name] => Open sciences & open data
[parent_slug] => open-science
)
[56] => WP_Term Object
(
[term_id] => 56
[name] => Regulatory strategy
[slug] => regulatory-strategy
[term_group] => 0
[term_taxonomy_id] => 56
[taxonomy] => issue
[description] =>
[parent] => 54
[count] => 14
[filter] => raw
[parent_name] => Other
[parent_slug] => other
)
[279] => WP_Term Object
(
[term_id] => 279
[name] => Reporting Requirements
[slug] => reporting-requirements
[term_group] => 0
[term_taxonomy_id] => 279
[taxonomy] => issue
[description] =>
[parent] => 51
[count] => 2
[filter] => raw
[parent_name] => Consortium structure & management
[parent_slug] => consortium-structure
)
[81] => WP_Term Object
(
[term_id] => 81
[name] => Representations & Warranties
[slug] => warranties
[term_group] => 0
[term_taxonomy_id] => 81
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 16
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[278] => WP_Term Object
(
[term_id] => 278
[name] => Roles & Responsibilities
[slug] => roles-responsibilities
[term_group] => 0
[term_taxonomy_id] => 278
[taxonomy] => issue
[description] =>
[parent] => 51
[count] => 3
[filter] => raw
[parent_name] => Consortium structure & management
[parent_slug] => consortium-structure
)
[108] => WP_Term Object
(
[term_id] => 108
[name] => Sublicenses
[slug] => sublicensee
[term_group] => 0
[term_taxonomy_id] => 108
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 4
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[268] => WP_Term Object
(
[term_id] => 268
[name] => Supply/Purchase of Products
[slug] => supply-purchase-of-products
[term_group] => 0
[term_taxonomy_id] => 268
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 18
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[62] => WP_Term Object
(
[term_id] => 62
[name] => Survival
[slug] => survival
[term_group] => 0
[term_taxonomy_id] => 62
[taxonomy] => issue
[description] =>
[parent] => 54
[count] => 0
[filter] => raw
[parent_name] => Other
[parent_slug] => other
)
[86] => WP_Term Object
(
[term_id] => 86
[name] => Technology transfer
[slug] => technology-transfer
[term_group] => 0
[term_taxonomy_id] => 86
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 6
[filter] => raw
[parent_name] => Information sharing & data safety
[parent_slug] => information-sharing
)
[52] => WP_Term Object
(
[term_id] => 52
[name] => Term & termination
[slug] => term-and-termination
[term_group] => 0
[term_taxonomy_id] => 52
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 2
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[76] => WP_Term Object
(
[term_id] => 76
[name] => Term of agreement
[slug] => term-of-agreement
[term_group] => 0
[term_taxonomy_id] => 76
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 14
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[74] => WP_Term Object
(
[term_id] => 74
[name] => Termination & withdrawal
[slug] => termination-and-withdrawal
[term_group] => 0
[term_taxonomy_id] => 74
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 15
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[88] => WP_Term Object
(
[term_id] => 88
[name] => Use of background IP
[slug] => use-background-ip
[term_group] => 0
[term_taxonomy_id] => 88
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 21
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
)
[issues_by_slug:GHIAA2019\MapguideSearch:private] => Array
(
[access-to-medicines] => WP_Term Object
(
[term_id] => 46
[name] => Access to medicines
[slug] => access-to-medicines
[term_group] => 0
[term_taxonomy_id] => 46
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[access-results] => WP_Term Object
(
[term_id] => 91
[name] => Access to results
[slug] => access-results
[term_group] => 0
[term_taxonomy_id] => 91
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 16
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[pricing] => WP_Term Object
(
[term_id] => 100
[name] => Affordable or reasonable pricing
[slug] => pricing
[term_group] => 0
[term_taxonomy_id] => 100
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 5
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[annexes] => WP_Term Object
(
[term_id] => 55
[name] => Annexes
[slug] => annexes
[term_group] => 0
[term_taxonomy_id] => 55
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[benefit-revenue-sharing] => WP_Term Object
(
[term_id] => 66
[name] => Benefit/revenue sharing
[slug] => benefit-revenue-sharing
[term_group] => 0
[term_taxonomy_id] => 66
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 4
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[business-model] => WP_Term Object
(
[term_id] => 53
[name] => Business model
[slug] => business-model
[term_group] => 0
[term_taxonomy_id] => 53
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 1
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[commercialization-strategy] => WP_Term Object
(
[term_id] => 58
[name] => Commercialization strategy
[slug] => commercialization-strategy
[term_group] => 0
[term_taxonomy_id] => 58
[taxonomy] => issue
[description] =>
[parent] => 55
[count] => 0
[filter] => raw
[parent_name] => Annexes
[parent_slug] => annexes
)
[confidentiality] => WP_Term Object
(
[term_id] => 84
[name] => Confidentiality
[slug] => confidentiality
[term_group] => 0
[term_taxonomy_id] => 84
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 33
[filter] => raw
[parent_name] => Information sharing & data safety
[parent_slug] => information-sharing
)
[conflict-of-interest] => WP_Term Object
(
[term_id] => 59
[name] => Conflict of Interest
[slug] => conflict-of-interest
[term_group] => 0
[term_taxonomy_id] => 59
[taxonomy] => issue
[description] =>
[parent] => 54
[count] => 2
[filter] => raw
[parent_name] => Other
[parent_slug] => other
)
[consortium-structure] => WP_Term Object
(
[term_id] => 51
[name] => Consortium structure & management
[slug] => consortium-structure
[term_group] => 0
[term_taxonomy_id] => 51
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 9
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[data-management] => WP_Term Object
(
[term_id] => 82
[name] => Data management
[slug] => data-management
[term_group] => 0
[term_taxonomy_id] => 82
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 11
[filter] => raw
[parent_name] => Information sharing & data safety
[parent_slug] => information-sharing
)
[dispute-resolution] => WP_Term Object
(
[term_id] => 267
[name] => Dispute resolution
[slug] => dispute-resolution
[term_group] => 0
[term_taxonomy_id] => 267
[taxonomy] => issue
[description] =>
[parent] => 54
[count] => 10
[filter] => raw
[parent_name] => Other
[parent_slug] => other
)
[donation] => WP_Term Object
(
[term_id] => 271
[name] => Donation
[slug] => donation
[term_group] => 0
[term_taxonomy_id] => 271
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 5
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[effect-of-termination] => WP_Term Object
(
[term_id] => 72
[name] => Effect of termination
[slug] => effect-of-termination
[term_group] => 0
[term_taxonomy_id] => 72
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 10
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[equitable-access] => WP_Term Object
(
[term_id] => 101
[name] => Equitable access
[slug] => equitable-access
[term_group] => 0
[term_taxonomy_id] => 101
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 8
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[exceptions-confidentiality] => WP_Term Object
(
[term_id] => 83
[name] => Exceptions and limitations to the confidentiality obligations
[slug] => exceptions-confidentiality
[term_group] => 0
[term_taxonomy_id] => 83
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 8
[filter] => raw
[parent_name] => Information sharing & data safety
[parent_slug] => information-sharing
)
[exceptions-ip-ownership] => WP_Term Object
(
[term_id] => 93
[name] => Exceptions or limitations to the IP ownership rules
[slug] => exceptions-ip-ownership
[term_group] => 0
[term_taxonomy_id] => 93
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 2
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[exploitation-results] => WP_Term Object
(
[term_id] => 92
[name] => Exploitation of results
[slug] => exploitation-results
[term_group] => 0
[term_taxonomy_id] => 92
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 13
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[funder-step-in] => WP_Term Object
(
[term_id] => 103
[name] => Funder step-in rights
[slug] => funder-step-in
[term_group] => 0
[term_taxonomy_id] => 103
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 1
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[global-access-plans] => WP_Term Object
(
[term_id] => 57
[name] => Global access plans
[slug] => global-access-plans
[term_group] => 0
[term_taxonomy_id] => 57
[taxonomy] => issue
[description] =>
[parent] => 55
[count] => 0
[filter] => raw
[parent_name] => Annexes
[parent_slug] => annexes
)
[indemnity] => WP_Term Object
(
[term_id] => 80
[name] => Indemnity / indemnification
[slug] => indemnity
[term_group] => 0
[term_taxonomy_id] => 80
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 17
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[information-sharing-information-sharing] => WP_Term Object
(
[term_id] => 257
[name] => Information sharing
[slug] => information-sharing-information-sharing
[term_group] => 0
[term_taxonomy_id] => 257
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 16
[filter] => raw
[parent_name] => Information sharing & data safety
[parent_slug] => information-sharing
)
[information-sharing] => WP_Term Object
(
[term_id] => 49
[name] => Information sharing & data safety
[slug] => information-sharing
[term_group] => 0
[term_taxonomy_id] => 49
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[insurance] => WP_Term Object
(
[term_id] => 109
[name] => Insurance
[slug] => insurance
[term_group] => 0
[term_taxonomy_id] => 109
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 6
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[ip-ownership] => WP_Term Object
(
[term_id] => 48
[name] => IP ownership & licensing
[slug] => ip-ownership
[term_group] => 0
[term_taxonomy_id] => 48
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[liability] => WP_Term Object
(
[term_id] => 50
[name] => Liability
[slug] => liability
[term_group] => 0
[term_taxonomy_id] => 50
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[limitation-of-liability] => WP_Term Object
(
[term_id] => 79
[name] => Limitation of liability/damage
[slug] => limitation-of-liability
[term_group] => 0
[term_taxonomy_id] => 79
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 23
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[material-transfer] => WP_Term Object
(
[term_id] => 85
[name] => Material transfer
[slug] => material-transfer
[term_group] => 0
[term_taxonomy_id] => 85
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 4
[filter] => raw
[parent_name] => Information sharing & data safety
[parent_slug] => information-sharing
)
[open-data] => WP_Term Object
(
[term_id] => 98
[name] => Open data
[slug] => open-data
[term_group] => 0
[term_taxonomy_id] => 98
[taxonomy] => issue
[description] =>
[parent] => 47
[count] => 10
[filter] => raw
[parent_name] => Open sciences & open data
[parent_slug] => open-science
)
[open-sciences] => WP_Term Object
(
[term_id] => 97
[name] => Open sciences
[slug] => open-sciences
[term_group] => 0
[term_taxonomy_id] => 97
[taxonomy] => issue
[description] =>
[parent] => 47
[count] => 8
[filter] => raw
[parent_name] => Open sciences & open data
[parent_slug] => open-science
)
[open-science] => WP_Term Object
(
[term_id] => 47
[name] => Open sciences & open data
[slug] => open-science
[term_group] => 0
[term_taxonomy_id] => 47
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[other] => WP_Term Object
(
[term_id] => 54
[name] => Other
[slug] => other
[term_group] => 0
[term_taxonomy_id] => 54
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[outbreak-preparedness] => WP_Term Object
(
[term_id] => 102
[name] => Outbreak preparedness
[slug] => outbreak-preparedness
[term_group] => 0
[term_taxonomy_id] => 102
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 4
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[ownership-background-ip] => WP_Term Object
(
[term_id] => 87
[name] => Ownership of background IP
[slug] => ownership-background-ip
[term_group] => 0
[term_taxonomy_id] => 87
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 17
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[ownership-results] => WP_Term Object
(
[term_id] => 89
[name] => Ownership of results
[slug] => ownership-results
[term_group] => 0
[term_taxonomy_id] => 89
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 29
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[pandemic-products] => WP_Term Object
(
[term_id] => 266
[name] => Pandemic Products
[slug] => pandemic-products
[term_group] => 0
[term_taxonomy_id] => 266
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 6
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[royalties-and-payments] => WP_Term Object
(
[term_id] => 70
[name] => Payment Structures
[slug] => royalties-and-payments
[term_group] => 0
[term_taxonomy_id] => 70
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 14
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[protection-results] => WP_Term Object
(
[term_id] => 90
[name] => Protection of results
[slug] => protection-results
[term_group] => 0
[term_taxonomy_id] => 90
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 16
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[public-health-licenses] => WP_Term Object
(
[term_id] => 107
[name] => Public health licenses
[slug] => public-health-licenses
[term_group] => 0
[term_taxonomy_id] => 107
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 5
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[publication] => WP_Term Object
(
[term_id] => 96
[name] => Publication
[slug] => publication
[term_group] => 0
[term_taxonomy_id] => 96
[taxonomy] => issue
[description] =>
[parent] => 47
[count] => 13
[filter] => raw
[parent_name] => Open sciences & open data
[parent_slug] => open-science
)
[regulatory-strategy] => WP_Term Object
(
[term_id] => 56
[name] => Regulatory strategy
[slug] => regulatory-strategy
[term_group] => 0
[term_taxonomy_id] => 56
[taxonomy] => issue
[description] =>
[parent] => 54
[count] => 14
[filter] => raw
[parent_name] => Other
[parent_slug] => other
)
[reporting-requirements] => WP_Term Object
(
[term_id] => 279
[name] => Reporting Requirements
[slug] => reporting-requirements
[term_group] => 0
[term_taxonomy_id] => 279
[taxonomy] => issue
[description] =>
[parent] => 51
[count] => 2
[filter] => raw
[parent_name] => Consortium structure & management
[parent_slug] => consortium-structure
)
[warranties] => WP_Term Object
(
[term_id] => 81
[name] => Representations & Warranties
[slug] => warranties
[term_group] => 0
[term_taxonomy_id] => 81
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 16
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[roles-responsibilities] => WP_Term Object
(
[term_id] => 278
[name] => Roles & Responsibilities
[slug] => roles-responsibilities
[term_group] => 0
[term_taxonomy_id] => 278
[taxonomy] => issue
[description] =>
[parent] => 51
[count] => 3
[filter] => raw
[parent_name] => Consortium structure & management
[parent_slug] => consortium-structure
)
[sublicensee] => WP_Term Object
(
[term_id] => 108
[name] => Sublicenses
[slug] => sublicensee
[term_group] => 0
[term_taxonomy_id] => 108
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 4
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
[supply-purchase-of-products] => WP_Term Object
(
[term_id] => 268
[name] => Supply/Purchase of Products
[slug] => supply-purchase-of-products
[term_group] => 0
[term_taxonomy_id] => 268
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 18
[filter] => raw
[parent_name] => Access to medicines
[parent_slug] => access-to-medicines
)
[survival] => WP_Term Object
(
[term_id] => 62
[name] => Survival
[slug] => survival
[term_group] => 0
[term_taxonomy_id] => 62
[taxonomy] => issue
[description] =>
[parent] => 54
[count] => 0
[filter] => raw
[parent_name] => Other
[parent_slug] => other
)
[technology-transfer] => WP_Term Object
(
[term_id] => 86
[name] => Technology transfer
[slug] => technology-transfer
[term_group] => 0
[term_taxonomy_id] => 86
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 6
[filter] => raw
[parent_name] => Information sharing & data safety
[parent_slug] => information-sharing
)
[term-and-termination] => WP_Term Object
(
[term_id] => 52
[name] => Term & termination
[slug] => term-and-termination
[term_group] => 0
[term_taxonomy_id] => 52
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 2
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[term-of-agreement] => WP_Term Object
(
[term_id] => 76
[name] => Term of agreement
[slug] => term-of-agreement
[term_group] => 0
[term_taxonomy_id] => 76
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 14
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[termination-and-withdrawal] => WP_Term Object
(
[term_id] => 74
[name] => Termination & withdrawal
[slug] => termination-and-withdrawal
[term_group] => 0
[term_taxonomy_id] => 74
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 15
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[use-background-ip] => WP_Term Object
(
[term_id] => 88
[name] => Use of background IP
[slug] => use-background-ip
[term_group] => 0
[term_taxonomy_id] => 88
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 21
[filter] => raw
[parent_name] => IP ownership & licensing
[parent_slug] => ip-ownership
)
)
[filter_issues:GHIAA2019\MapguideSearch:private] => Array
(
)
)
